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Drug-related deaths & deaths 
among drug users, 2012
The latest figures on drug-related deaths and deaths among drug users in Ireland, up to 2012, 
have been published.1 The number of deaths has decreased slightly from 645 in 2011 to 633 
in 2012. Of the total number of deaths in 2012, 350 people died as a result of poisoning (i.e. 
toxic effect of drug[s] in the body), and 283 were drug users who died as a result of trauma, 
such as hanging, or from a medical cause, for example liver disease. It is important to note that 
the figures in this update supersede all previously published figures. Similarly, figures for 2012 
will be revised when data relating to new cases become available, i.e. as more inquest cases 
close. For example, in January 2014 the number of drug-related deaths for 2011 was 607, but 
over the past 11 months this has risen to the 645 figure we now have recorded.
In the nine-year period 2004–2012, a total of 5,289 deaths by drug poisoning and deaths 
among drug users met the criteria for inclusion in the National Drug-Related Deaths Index 
(NDRDI) database. Of these deaths, 3,112 were due to poisoning and 2,177 were deaths 
among drug users (non-poisoning) (Table 1). Deaths due to polydrug use have increased by 
60% over the reporting period, from 118 in 2004 to 189 in 2012.
Poisoning deaths, 2012
The annual number of poisoning deaths decreased from 387 in 2011 to 350 in 2012 (Table 
1).  As in previous years, the majority (74%) in 2012 were male; the median age of those who 
died was 40 years, again similar to previous years. 
In 2012, alcohol was, once again, the drug most commonly involved in poisoning deaths 
(36%). Prescription drugs played a significant part in poisoning deaths, with over a third (35%) 
of these deaths involving benzodiazepines. Methadone was implicated in a quarter of deaths, 
with the majority (87%) involving polydrugs. Antidepressants were implicated in a quarter 
(25%) of deaths, with females accounting for almost half (46%) of these deaths.
Dr Suzi Lyons and Ena Lyn of the Health Research Board at the launch of Drug-related deaths and deaths 
among drug users in Ireland 2012 in December.
Comparing European 
drugs strategies
See page 4
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Joan Moore
Joan Moore, former content editor of Drugnet Ireland, died 
in January 2015. Joan had been one of the longest serving 
members of HRB staff and had spent most of the last 10 
years working with the drug and alcohol research team. We 
greatly admired Joan’s erudition and intellectual gifts and 
her skilful management of much of the HRB’s published 
output and we know from her family that she brought the 
same enthusiasm and enjoyment of work to the practical 
tasks in her home. So, it is poignant that she never got to 
use her retirement present, a workbench on which she had 
planned to hone her carpentry skills with the same diligence 
as she used to keep abreast of developments in editing and 
scientific communication. 
Joan loved language and writing and was drawn to the silly 
and absurd and great story telling of every kind from The 
loved one and Scoop, an obvious favourite for an editor, to 
the wonderful Yon lion’s et our Albert. We lost her technical 
gifts when she retired but it is her wit and wisdom that 
we now remember most. She was genuinely interested in 
and concerned with the minutiae of her workmates’ lives 
and willingly shared the joys and concerns of her own 
beloved family. To them, Paul her husband, Tim her son 
and our good friend Katie, her daughter, we express our 
deepest sympathies.
Brian Galvin Need hi-res
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Drug-related deaths 2012 (continued)
The number of poisoning deaths in which heroin was 
implicated continues to decline, falling by 47% to 61 in 
2012, compared to a peak of 115 in 2009.
Over half (54%) of all poisoning deaths in 2012 involved 
more than one drug (polydrug use). Over a third (37%) of 
those who died from poisoning in 2012 had a history of 
mental illness.
Non-poisoning deaths, 2012
The number of non-poisoning deaths recorded among drug 
users increased to 283, compared to 258 in 2011 (Table 1). 
Where the specific cause of death is known, these deaths are 
categorised as being due to either trauma or medical causes 
(Figure 1).
Deaths due to trauma
The number of deaths due to trauma increased in 2012 to 
138 deaths from 124 in 2011, an increase of 11% (Figure 
1). The majority (72%) of those who died were aged under 
39 years. The median age was 29 years. As in previous years, 
the majority (82%) were male. The most common causes 
of death due to trauma were hanging (52%) and drowning 
(14%). Of note is the increasing number of deaths due to 
hanging, from 53 deaths in 2010 to 72 in 2012. Over half 
(52%) of those who died from traumatic causes in 2012 had 
a history of mental illness.
Deaths due to medical causes
The number of deaths due to medical causes increased by 
8% in 2012 to 143 deaths, from 132 in 2011 (Figure 1). 
The majority of those who died (67%) were aged between 
35 and 59 years. The median age was 46 years. Males 
accounted for 70% of those who died due to medical causes. 
The most common medical causes of death were cardiac 
events (31%) and liver diseases (16%). 
(Ena Lynn)
1. Health Research Board (2014) Drug-related deaths and 
deaths among drug users in Ireland: 2012 figures from 
the National Drug-Related Deaths Index.  http://www.
drugsandalcohol.ie/23003 
 
2004 2005 2006 2007 2008 2009 2010 2011 2012
All deaths 432 505 561 626 626 656 605 645 633
Poisonings (3,112) 267 300 325 382 386 374 341 387 350
Non-poisoning (2,177) 165 205 236 244 240 282 264 258 283
Table 1: Number of deaths, NDRDI 2004–2012 (n=5,289)
drugs and illegal drugs, such as heroin, cocaine and MDMA.
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2004 2005 2006 2007 2008 2009 2010 2011 2012
Medical 55 68 105 114 121 132 133 132 143
Trauma 92 118 124 120 112 136 125 124 138
Figure 1: Non-poisoning deaths among drug users, NDRDI 2004–2012 (n=2,092)
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16th annual Service of Commemoration 
and Hope
On Sunday 1 February 2015 the National Family 
Support Network (NFSN) held its 16th annual Service of 
Commemoration and Hope in remembrance of loved ones 
lost to substance misuse and related causes. Its purpose is 
to publicly support and offer hope to families living with the 
devastation that substance misuse causes.
Those in attendance included the Lord Mayor of Dublin, 
Christy Burke; Commander Kieran Carey, aide-de-camp 
to the Taoiseach; Garda Commissioner Noirín O’Sullivan; 
Bishop Éamonn Walsh, Auxiliary Bishop of Dublin, and other 
religious representatives; and family members, friends, and 
many people working in the drugs area. Music was provided 
by the soprano Linda Allen and the North Dublin Community 
Gospel Choir.
In her address to the gathering, Sadie Grace of the NFSN 
spoke about the latest report from the National Drug-Related 
Deaths (NDRDI). For the period 2004 to 2012 a total of 
5,289 deaths were recorded by the NDRDI. Of these deaths, 
3,112 were due to poisoning and 2,177 were deaths among 
drug users. She spoke about the increase in deaths due to 
polydrug use and the fact that the majority of those who 
died were young men. 
Sadie Grace also spoke about the compounding factors 
affecting bereaved families, such as media coverage, 
increased financial difficulties and single parents or 
grandparents taking on caring responsibilities for young 
children. She mentioned the role of naloxone in preventing 
deaths from opiate overdose and the NFSN’s support for 
the HSE naloxone demonstration project. She stressed 
the importance of expanding the availability of naloxone 
nationwide. The NFSN will be presenting Minister for 
Health Leo Varadkar with a petition requesting nationwide 
availability of naloxone.
In his reflection, Fr Edmond Grace SJ talked about the pain 
families have gone through and the need to acknowledge 
the loss but also to build on the strength of hope. Sandra 
Hill, a member of the NFSN Bereavement Support Group, 
gave a moving testimony about her positive experience as 
part of this group in dealing with the death of her brother. 
She sincerely acknowledged the tremendous work of the 
NFSN Bereavement Support Group and encouraged family 
members looking for help to contact the NFSN.
Poet and playwright Paula Meehan recited her poem ‘Pray for 
the children of longing’. Susan Scally of the Drugs Policy Unit 
read a message on behalf of Pope Francis. Kenny Hartnett, 
chair of SURF (Service Users’ Representative Forum), gave 
an honest and emotional speech about his experience as a 
drug user. In his address on behalf of Archbishop Diarmuid 
Martin, Bishop Éamonn Walsh spoke about the importance of 
acknowledging and never losing sight of the dignity of every 
person. Daniella Jurj of the New Communities Partnership 
recited a poem of hope, ‘Seasons of Grief’. Sister Geraldine 
Byrne of The Oasis Centre,a professional counselling 
and therapy service in Dublin, spoke about how every 
bereavement is a very personal and individual experience. 
She encouraged people affected by bereavement to seek 
support. 
(Ena Lynn)
You can contact the National Family Support Network at:
16 Talbot Street, Dublin 1
Telephone: 01-836-5168
email: info@fsn.ie
web: www.fsn.ie 
How does Ireland’s drugs policy 
compare with others?
Two studies comparing the drug policies of different 
European countries, including Ireland, have recently been 
published. One compares the ‘governance’ of addictions 
across the member states of the EU and Norway, and the 
other examines the ‘coherency’ of policies on psychoactive 
substances (illicit drugs, alcohol and tobacco) across seven 
member states of the Council of Europe.
The governance of addictions
This comparative assessment was undertaken by ALICE 
RAP (Addictions and Lifestyles in Contemporary Europe – 
Reframing Addictions Project), a European research project, 
co-financed by the European Commission.1 ALICE RAP’s 
assessment was premised on the argument that addictions 
inflict an excessive burden not only on individuals but 
also on societies as a whole. Moreover, in the 21st century, 
Western societies are being forced to adjust their policies 
to new realities which include a growing diversity of 
consumption scenarios, their progressive normalisation in 
some contexts and even their trivialisation in others. The 
comparative assessment sought to discover, to what extent 
do the policies of different member states respond to the 
new and emerging circumstances.
The authors used ‘strategy’ and ‘structure’ to analyse 
similarities and differences (the degree of ‘convergence’) 
between member states’ addiction policies. They asked 
a question in relation to each of these two dimensions of 
governance, linking them to the content of the policy and 
the extent to which individual member states are pursuing a 
‘traditional’ as opposed to more innovative approaches. 
•	 Strategy: To what extent does the strategy adopt a 
‘safety-and-disease’ focus or display a wider interest in 
‘relational management of well-being’ across society as 
a whole? 
•	 Structure: What substances are included in the strategy, 
and does it expand beyond misuse of addictive 
substances to encompass addictive activities such  
as gambling? 
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The authors identified four clusters of countries, reflecting 
four different models of ‘governance of addictions’. Ireland is 
deemed to be in a handy enough position but is not among 
Europe’s ‘trend-setters’ (see Table 1). 
The authors see the first model – ‘Trend-setters in illicit 
substances’ – as the model towards which all countries might 
consider aspiring. This model is characterised mainly by its 
strategy for illicit substances, giving considerable importance 
to harm reduction policies such as needle exchanges and 
injection rooms. Another distinguishing characteristic is 
that all eight countries linked with this model decriminalise 
possession of illicit substances. 
With regard to the six countries linked to the second model, 
including Ireland, the authors see these countries as having 
developed ‘a regulatory approach to licit substances and loose 
measures to combat illicit substances’. They attribute these 
two separate trajectories to the heavy consumption of alcohol 
in these jurisdictions. The authors also note that these are the 
six countries in the sample that use evidence-based regulation 
on alcohol and tobacco, but that only the United Kingdom 
consistently implements best-practice interventions. Moreover, 
the countries associated with model 2 do not implement as 
many innovative policies as the countries associated with 
model 1, and neither are they  
as proactive. 
With regard to ‘structure’, the countries linked with model 
2 are all classified as having a comprehensive policy-making 
structure, tending to combine legal and illicit substances, 
involving non-profit organisations in decision-making, having 
an ad hoc co-ordinating body, decentralising implementation, 
and having a long history of legislating for illicit substances. 
The authors conclude that these countries, including Ireland, 
could build on their comprehensive structure and their well-
being and relational management approach, by extending it 
towards illicit substances (see Figure 1). 
Figure 1: Governance of addictions: European models  
and visions
Source: after Figure 8.2 in Ysa et al. 20141
Coherency of policies on psychoactive substances
The second comparative assessment, undertaken by the 
Council of Europe’s Pompidou Group, whose mission is to 
contribute to the development of multidisciplinary, innovative, 
effective and evidence-based drug policies in member states, 
similarly found that Ireland is in a handy enough position, 
but is not at the forefront, in relation to the coherency of its 
policies on different psychoactive substances, namely illicit 
drugs, alcohol and tobacco.2 The assessment comprises a 
series of case studies; the authors of each case study assessed 
the coherency of the policies in their country in relation to the 
World Health Organization’s overarching population-based 
health goal – ‘a state of complete physical, mental and social 
well-being and not merely the absence of disease or infirmity’. 
The case study on Ireland shows that, of the three national 
policies on psychoactive substances, tobacco is the one most 
consistently aligned with a population-based approach to 
health. Two initiatives that will shift alcohol policy in Ireland 
closer to a population-based approach are noted: (1) in 2012 
the National Substance Misuse Strategy Steering Committee 
published its report, calling for a population-based approach 
to alcohol misuse, and (2) in 2013 the first public health bill 
in Ireland to focus on alcohol measures was being drafted. 
At the time of going to press, however, neither initiative had 
been fully implemented. The case study reports a population-
based approach in the planned response to problematic drug 
use. However, because of the criminal activity, public disorder, 
anti-social behaviour and violence that may be associated 
with illicit drugs, criminal justice responses have been adopted 
as well. While these latter measures may achieve the desired 
criminal justice outcomes, the report observes that they 
undermine the move towards a population-based approach  
to health by criminalising and/or stigmatising problem  
drug users. 
The case study on Ireland concludes: 
This continuing lack of coherence among policies on various 
psychoactive substances, particularly alcohol and illicit 
drugs, in relation to an over-arching population-health 
objective, may be expected to hinder the realisation of ‘a 
complete state of physical, mental and social well-being and 
not merely the absence of disease or infirmity’ among the 
Irish population. (p. 189)
(Brigid Pike)
1. Ysa T, Colom J, Albareda A, Ramon A, Carrion M and Segura 
L (2014) Governance of addictions: European public policies. 
Oxford: Oxford University Press. For more information on 
ALICE RAP, visit http://www.alicerap.eu.
2. Muscat R, Pike B and members of the Coherent Policy Expert 
Group (2014) Coherence policy markers for psychoactive 
substances. Strasbourg: Council of Europe Publishing.  
http://www.coe.int/T/DG3/Pompidou/default_en.asp 
Comparing national drugs policies (continued)
Comprehensive policy: 
addictions and lifestyle 
Safety and disease 
approach
Relational 
management of well-being
Substance-based 
reactive intervention
MODEL 4: 
TRADITIONAL 
APPROACH
MODEL 3: 
TRANSITIONING
MODEL 2: 
REGULATION 
OF LEGAL 
SUBSTANCES
MODEL 1: 
TRENDSETTERS 
IN ILLICIT 
SUBSTANCES
Table 1: Models of governance of addictions in Europe 
Model Characteristics Countries
Trend-setters in illicit 
substances
Combine a well-being and relational management strategy with a comprehensive 
structure. Focus on illicit substances through harm reduction. Low rankers on legal 
policy scales. 
Belgium, Czech Republic, Germany, Italy, 
Luxemburg, Netherlands, Portugal and Spain
Regulation of legal 
substances 
Combine a well-being and rational management structure. Focus on legal substances 
(tobacco and alcohol). No decriminalisation of possession.
Finland, France, Ireland, Norway, Sweden  
and UK
Transitioning model Countries transitioning, mostly from the traditional model to a more comprehensive 
one, but still with a substance separation approach. Do not decriminalise possession.
Austria, Bulgaria, Cyprus, Denmark, Poland and 
Slovenia
Traditional approach These countries embrace an individualistic and safety- and disease-based 
approach, combined with and organisational structure based on approaching 
substances separately.
Estonia, Greece, Hungary, Latvia, Lithuania, 
Malta, Romania and Slovakia
Source: Table 8.1 in Ysa et al.1
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Women and non-medical use of 
prescription drugs (NMUPD)
Understanding the gender dimension of drug use and drug 
use disorders is a critical requirement in developing effective 
policy and practice. A ground-breaking study by the Council 
of Europe’s Pompidou Group investigates women’s use of 
prescription drugs for non-medical reasons, i.e. women 
who have been prescribed a medication by a doctor but are 
continuing to use it without the doctor’s approval, OR they 
have obtained the medication from somebody else, not an 
authorised prescriber.1
The aims of the study are to:
 ■ explore gender differences in NMUPD in Europe and 
the Mediterranean region through a documentation 
of secondary sources, with the aim of constructing a 
snapshot of the current scenario;
 ■ identify gaps in the data available; and
 ■ make recommendations for further research, for policy 
development and practice.
Following a literature review, a survey questionnaire was 
developed and administered to respondents in 17 countries: 
Cyprus, Czech Republic, Egypt, France, Germany, Greece, 
Ireland, Israel, Italy, Lebanon, Lithuania, Malta, Morocco, 
Serbia, The Netherlands, Tunisia and Wales (see map).
Findings
The literature review shows that women are a high-risk 
category for non-medical use of prescription drugs, and 
that the pattern of use is different among men and women; 
the pattern of use and non-medical use varies according to 
the category of prescription medication; and trauma and 
interpersonal violence may be causal factors leading to non-
medical use of prescription drugs among women. 
The data submitted by the 17 countries show that, in the 
general population, the use of prescription drugs is higher 
among females than among males. Prescription drug use 
increases with age: the report highlights the Irish data which 
shows that the 30s are the highest risk period. 
Only six of the 17 countries could report on non-medical 
use of prescription drugs, and Ireland is not one of them. 
As a result, the full extent of NMUPD across all jurisdictions 
cannot be known and gender differences cannot  
be detected.  
Recommendations
A selection of the recommendations made on foot of 
the investigation to the Permanent Correspondents of 
the Pompidou Group, including the Irish Permanent 
Correspondent, are noted below.
Monitoring and research
 ■ Recommend to researchers that in addition to the use of 
‘sedatives and tranquillisers’, the use of other categories 
of prescription medication be included as items in the 
general population survey.
 ■ Ask researchers to ensure that the item on the source of 
the prescription medication be included in the general 
population survey as a core item. 
 ■ Ask researchers to develop mechanisms for the 
monitoring of emergency department visits and 
admissions. Currently in Ireland only emergency hospital 
admissions owing to misuse of prescription medications 
are recorded and not visits to emergency departments. 
As a result, the morbidity, as distinct from mortality, 
associated with use and non-medical use of prescription 
medications, is under-recorded.
 ■ Ask the European Monitoring Centre on Drugs and Drug 
Addiction (EMCDDA) to include, in the common core 
general population survey, items relating to the use of 
prescription medication and to the non-medical use 
of prescription medication, and that the defining and 
reporting on the extent of NMUPD become a priority.
 ■ Ask the EMCDDA to develop a clear method of 
distinguishing the monitoring of both prescription 
practices and NMUPD.
 ■ Ask the ESPAD to expand the categories of prescription 
drugs monitored and to consider including ‘prescription 
drug use’ and not just ‘use without a prescription’. 
Practice (prevention and treatment)
 ■ Offer differentiated responses to meet different needs  
of women in relation to prevention, harm reduction  
and treatment. 
 ■ Develop educational programmes for patients on safe use 
and disposal of prescribed medicines.
 ■ Develop guidelines for prescribing practices that reduce 
unnecessary prescriptions and the potential for diversion.
 ■ Train doctors to identify those at risk of dependence 
in order to hinder their movement along the addictive 
career path.
Policy
 ■ Develop coherent policies that address the use and 
misuse of prescription medications and make specific 
reference to gender.
 ■ Commission studies dedicated exclusively to NMUPD and 
address specific issues such as the initiation, escalation, 
physical and psychosocial consequences in relation to 
women as an ‘at risk’ category.
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 ■ Develop state-level prescription drug monitoring 
programmes.
 ■ Develop educational programmes targeted towards 
patients on how to safely use, store and dispose of 
prescribed medicines.
Violence against women and NMPUD
 ■ Having reviewed the findings of the literature review 
on the possible links between trauma and interpersonal 
violence and NMUPD among women, the Gender 
Equality Commission Secretariat of the Council of Europe 
calls on all member states to go further – to hold round-
tables bringing together international organisations 
active in the field to present examples of their good 
practice, and to commission studies on the relationship 
between violence against women and NMPUD within 
their own jurisdictions. 
(Brigid Pike)
1. Clark M and expert working group and participants (2014) 
The gender dimension of non-medical use of prescription drugs 
(NMUPD) in Europe and the Mediterranean region [P-PG/
Gender (2014) 8] http://www.drugsandalcohol.ie/22964/ 
Women & NMUPD (continued)
The challenge of controlling new 
psychoactive substances (NPS)
The number and diversity of new psychoactive substances 
(NPS) reported in Europe in recent years represent a major 
challenge for Europe’s policymakers. In 2013, 81 NPS were 
notified to the EU early-warning system (EU–EWS),1 bringing 
the number of substances monitored to more than 350. As 
part of its Perspectives on Drugs (POD) series (see separate 
report on POD elsewhere in this issue), the European 
Monitoring Centre on Drugs and Drug Addiction (EMCDDA) 
has published an online and interactive analysis of the 
policy and legal challenges posed by NPS for European legal 
systems.2 This article summarises the key points arising out of 
this POD analysis.
The diversity of new substances and the speed with which 
they have been appearing provide a challenge for the 
criminal law which, in keeping with the fundamental 
principle of legal certainty,3 must be specific when defining 
an offence. In practice, this means that the drug law must 
clearly list all substances under its control: ‘The traditional 
response to the discovery of a new “drug”, established at a 
time when such a discovery was a relatively rare event, was 
to assess the risk to public health and add it to the national 
list of controlled substances’ (p. 1). However, the emergence 
of many new substances with limited evidence of health risks 
‘both challenges existing process and potentially stretches 
the credibility of control systems’. In some countries criminal 
laws must be agreed by parliament, and updating the law 
can be time consuming, and even where an NPS is identified 
and controlled, it is quickly replaced in the drug market.
In response to this challenge, a number of innovative legal 
responses have been developed throughout Europe. In 
general, three broad, sometimes overlapping, approaches 
have been adopted. 
Controls using consumer safety or medicines legislation
Consumer safety laws were used in Poland and these led 
to ‘mass “headshop” closures’ (p. 2). In Italy, regulations 
requiring goods or food for sale to be accurately labelled as 
to their expected use were employed to confiscate Spice (i.e. 
synthetic cannabinoid) products that were not labelled in 
Italian. In the UK, a similar approach was used to prevent the 
sale of mephedrone that was labelled as bath salts and plant 
food. In at least eight countries, medicines laws have been 
used to control NPS. By classifying an NPS as a medicinal 
product, a national medicines agency can demand a licence 
for importation, marketing or distribution. This can also have 
the effect of avoiding the criminalisation of users.
Extending and adapting existing laws and processes
Some countries have introduced ‘temporary control 
regimes’ in order to accelerate legal processes and allow 
time for NPS to be investigated for possible legal control. 
In the UK, a procedure was introduced in 2011 allowing 
for the temporary control of named substances for up 
to one year. Similar approaches were adopted in Latvia, 
Slovakia and Hungary. Some countries have chosen to 
extend the coverage of existing drug laws by listing defined 
groups of substances rather than individual drugs as was 
done previously. A generic group system, which includes 
a precise definition of a family of substances, has been 
the approach traditionally taken in Ireland and the UK. 
Other countries such as Latvia and Bulgaria use a broader 
‘analogue’ approach, which includes a more general 
definition of ‘similarity in pharmacological activity’, as well 
as ‘similarity in chemical structure’. Group definitions are 
now being adopted by many countries (Luxembourg, Italy, 
Cyprus, Lithuania, Denmark, France and Norway). Germany 
is considering adopting such a group system while the 
Netherlands has recently rejected such an approach owing 
to the ‘complexity of targeting some substances while not 
restricting others that may have legitimate uses’ (p. 3).
New laws to manage the unauthorised distribution  
of NPS
Ireland’s Criminal Justice (Psychoactive Substances) Act  
2010 is an example of a new law. A similar approach has 
been adopted in Austria, Portugal and Romania, although 
precise legal definitions, the nature of the threat posed by 
NPS and the possible penalties that can be imposed differ 
between countries. 
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Financing drug policy during  
the recession 
A recent EMCDDA Paper explores how the economic 
recession that started in 2008 affected public spending 
on drug-related initiatives in EU member states, including 
Ireland.1 The authors used quantitative and qualitative data 
provided in the annual reports of the national focal points 
(NFPs), including the Irish NFP based in the Health Research 
Board. Using this data, they examined public expenditures 
on health, social protection and public order and safety, as 
these are the areas of government activity where most drug-
related activities are provided. The authors concluded:
 ■ Austerity has led to reductions in spending in those 
categories of government activity that encompass most 
drug-related initiatives.
 ■ Countries that experienced greater levels of austerity 
tended to show greater reductions in expenditure.
 ■ Bigger cuts in public expenditure were registered in 
health than in public safety and social protection.
The authors divided the27 EU countries and Norway into 
four groups according to the severity of the impact of the 
economic recession in each country. Ireland falls into the 
fourth group of countries, along with Greece, Spain, Latvia, 
Lithuania, Portugal and Slovakia – Group 4 – which includes 
the countries hardest hit by the economic recession. In 2009, 
on average, the GDP of these Group 4 countries fell by close 
to 7% (5.5% in Ireland), and in the two subsequent years 
recovery was weakest among these countries: in 2011 youth 
unemployment was on average 35.5% (29.1% in Ireland) 
and total unemployment 16% (14.7% in Ireland).
Public expenditure on health, social protection and public 
order and safety
Among the Group 4 countries, the pattern of growth of 
public expenditure components that encompassed most 
drug-related activities changed markedly. Between 2000 
and 2007, expenditure grew faster on average in Group 4 
countries than in the other groups; after economies went 
into recession, the biggest falls in expenditure occurred 
in Group 4 countries. Health expenditure was particularly 
hard hit, declining in real terms by 7.0% in 2010 and 4.6% 
in 2011, on average. Expenditure on social protection also 
fell markedly, especially taking into account the increase 
observed in unemployment (down 1.1% in 2010 and 2.3% 
in 2011). Public order and safety expenditure managed to 
maintain a very modest real growth rate (0.4%) in 2010, but 
this was not sustained in 2011 (down 3.3%). The pattern of 
changes in Ireland was broadly similar (see Table 1). 
The authors conceded that drug-related expenditures 
represent a small proportion of these aggregates, and it 
cannot be inferred that public spending on drug initiatives 
necessarily behaved in a similar manner. However, they 
suggested that reductions in funding in these areas may have 
had an indirect impact on drug-related initiatives. 
Public expenditure on drug-related initiatives
With regard to specific drug-related public spending, 
the authors noted that among Group 4 countries, trend 
analysis of labelled drug-related public expenditure was only 
possible for Ireland, where it was found that drug-related 
public expenditure increased between 2005 and 2008 but 
decreased after 2008, probably owing to the public austerity 
measures that followed the economic recession. In 2009, 
the need to achieve a ‘prudent fiscal outturn’ led to an 
attempt to cut labelled drug-related expenditure across all 
government bodies in Ireland, and between 2008 and 2013 
public expenditure on drug-related programmes declined 
overall by 15.3% (see Table 2). 
Seeking greater cost-effectiveness
Ireland is reported as one of the countries that adopted 
policies specifically to either limit the potential damage of 
austerity or take advantage of the adverse period to improve 
efficiency. The Reitox NFP reports on Ireland, on which the 
authors of this EMCDDA Paper drew, describe a number 
of reports completed during the recession identifying 
opportunities for making savings, especially administrative 
efficiencies.2 The authors also noted a report by one regional 
drugs task force which, in anticipation of a decline in 
funding, commissioned a study to evaluate the effectiveness 
and efficiency of its 30 projects. 
2000–2008 
(average) 
2009 2010 2011
Health 7.5 3.7 -4.1 -6.3
Social Protection 7.0 15.4 2.1 0.1
Public Order and 
Safety 
5.5 -3.0 -2.2 -3.0
Table 1: Yearly growth rate in public expenditure (%)  
on health, social protection, and public order and safety, 
Ireland 2000–2011 (constant prices)
Common trends
Although different approaches have been adopted 
throughout Europe to NPS, two common trends are 
identifiable: ‘[First] there appears to be a general move 
towards the use of the threat of prison to deter suppliers; 
and, second,… countries are choosing not to use criminal 
sanctions for those possessing a new substance for personal 
use’ (p. 3).
(Johnny Conolly)
1. When a new psychoactive substance is detected on 
the European market, EU member states ensure that 
information on the manufacture, traffic and use of the 
drug is transmitted to the EMCDDA and Europol via their 
national networks (the Reitox national focal points and 
the Europol national units). This information exchange 
mechanism is the EU-EWS on NPS.
2. EMCDDA (2013) Controlling new psychoactive substances. 
See online edition with interactive features at http://www.
emcdda.europa.eu/topics-a-z 
3. In the common law tradition, legal certainty is often 
explained in terms of citizens’ need to be able to organise 
their affairs in such a way that they do not break the law.
Controlling NPS (continued)
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Outcomes
The authors concluded that a full analysis of the impact of 
the recession on drug initiatives will only be possible after 
some period of delay. They cited a 2014 OECD report on the 
impact of the economic recession:3
It is still too early to quantify the longer-term effects 
on people’s health, but unemployment and economic 
difficulties are known to contribute to a range of 
health problems, including mental illness… Short-
term savings may translate into much higher costs in 
the future, and governments should make funding of 
investment-type programmes a priority… Maintaining 
and strengthening support for the most vulnerable 
groups must remain a crucial part of any strategy for 
an economic and social recovery. (pp. 11–12)
(Brigid Pike)
1. European Monitoring Centre for Drugs and Drug Addiction 
(2014) Financing drug policy in Europe in the wake of 
the economic recession. EMCDDA Papers. Luxembourg: 
Publications Office of the European Union. http://www.
drugsandalcohol.ie/23115/ 
2. See accounts of these reports in Section 3.4 ‘Economic 
Analysis’ of the Health Research Board’s Reitox National 
Focal Point national reports to the EMCDDA for 2010 
and 2012, which may be accessed respectively at http://
www.drugsandalcohol.ie/14714/ and http://www.
drugsandalcohol.ie/18808/ 
3. OECD (2014) Society at a glance 2014: the crisis and its 
aftermath. OECD Social Indicators. Paris: OECD Publishing. 
http://dx.doi.org/10.1787/soc_glance-2014-en
Drug policy during the recession (continued)
2008
€ million 
2009 
€ million
(% change)
2010
€ million 
(% change)
2011
€ million 
(% change)
2012
€ million 
(% change)
2013
€ million 
(% change)
276.429 277.240 (0.3%) 267.792
(-3.4%)
249.839
(-6.7%)
242.342 
(-3.0%)
237.147
(-2.2%)
Table 2: Public expenditure directly attributable to drugs programmes, Ireland 2008–2013
Towards UNGASS 2016
Since Issue 48, Drugnet Ireland has carried ‘Towards UNGASS 
2016’ as a regular column. It reports on policy initiatives, 
research and debates launched by UN member states and civil 
society organisations in the lead-up to the UN General Assembly 
Special Session (UNGASS) on the world drug problem, due to be 
held in 2016 (A/RES/67/193).
On 30 October 2014 Drugs: international comparators 
was published by the UK government. This report 
describes policy and operational responses to drugs in 
other countries and reviews the evidence for their impact. 
Countries visited for the study included Canada, the Czech 
Republic, Denmark, Japan, New Zealand, Portugal, South 
Korea, Sweden, Switzerland, the USA and Uruguay. In their 
foreword to the report, the Home Secretary Theresa May 
MP and Minister of State Norman Baker MP state that 
while countries are dealing with similar issues and there 
are common elements in the responses, there are also 
stark differences in emphasis, often influenced by different 
social and legal contexts. They comment: ‘What works in 
one country may not be appropriate in another. … [the 
differences] illustrate the complexity of the challenge, and 
demonstrate why we cannot simply adopt another country’s 
approach wholesale.’ 
The report focuses on a series of responses to illicit drugs 
which the authors deem ‘particularly innovative, widely 
discussed, or relevant to the UK situation’. They are:
 ■ drug consumption rooms,
 ■ heroin-assisted treatment,
 ■ dissuasion commissions,
 ■ drug courts,
 ■ prison-based treatment 
 ■ prison-based harm reduction,
 ■ new psychoactive substances,
 ■ supply-side regulation of cannabis, and
 ■ decriminalising the possession of cannabis for  
personal use.
https://www.gov.uk/government/publications/drugs-
international-comparators 
On 7 January 2015 Measurement matters: designing new 
metrics for a drug policy that works was published by the 
Igarapé Institute, a Brazilian-based think-and-do-tank that 
focuses on emerging security and development issues; the 
Institute serves as the Secretariat to the Global Commission 
on Drug Policy. This new strategic paper introduces a 
preliminary set of six goals, 16 targets and 86 indicators 
to help guide governments, law enforcement agencies, 
health institutions and civil society in crafting more effective 
and efficient drug policy. According to one of the authors, 
‘conventional drug policy metrics … tell us how tough  
we´re being, but say nothing about whether we´re successful 
or not’. 
Under two high-level impacts – improving the health and 
welfare of the population, and enhancing security and  
safety of people – Measurement matters proposes six over-
arching goals:
 ■ end criminalisation and stigmatisation of drug users, 
 ■ curb drug use through public health measures, 
 ■ diminish rate of incarceration of non-violent drug-related 
offenders, 
 ■ target violent organised crime groups and traffickers, 
 ■ provide meaningful alternatives to illicit crop production, 
and 
 ■ encourage experimentation with different approaches to 
regulating drugs.
http://www.globalcommissionondrugs.org/
measurement-matters-designing-new-metrics-for-a-drug-
policy-that-works/ 
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Towards UNGASS 2016 (continued)
On 21 January 2015 Options and issues regarding 
marijuana legalization was published by the US-based 
RAND Drug Policy Research Center. The paper reviews recent 
changes in marijuana policies and the decisions that confront 
jurisdictions considering alternatives to traditional marijuana 
prohibition. The objective is to provide readers with ‘some 
tools for assessing the options and to help them appreciate 
the uncertainties’ (p. 12). 
The authors point out that marijuana policy is not a binary 
choice between prohibition and the for-profit commercial 
model. Legalisation encompasses a wide range possible 
regimes, determined by answering three key questions:
 ■ Who would be allowed to supply legal marijuana?
 ■ Would legal marijuana be taxed and, if so, how?
 ■ How would legal marijuana be regulated?
The costs and benefits of legalising marijuana also need to 
be considered. The authors stress that ‘the relevant policy 
question is not whether marijuana’s current harms outweigh 
its benefits but whether and how legalisation might change 
those harms and benefits and in which direction’ (p. 11). 
On the costs side, the authors acknowledge ‘clear and 
acute health effects’ associated with use, especially heavy 
use, of marijuana. However, they note some ‘fundamental 
limitations’ of the evidence: although marijuana use is 
correlated with many adverse outcomes, it is difficult to 
ascertain whether marijuana causes those outcomes; other 
factors confounding the conclusions to be drawn from 
research findings include the context of use – whether in 
an illegal or a legal context – and how this has influenced 
use, and the ‘largely unmeasured amounts of cannabinoids’ 
involved in observational data. 
On the benefits side, the authors note that some benefits 
of no longer enforcing laws against marijuana are medical 
benefits, gains in personal liberties, and the benefits of 
reduced arrest and sanctioning of marijuana offenders. In 
addition, the authors comment that self-reported medical 
and non-medical benefits of using marijuana are ‘real and 
that they should matter, but they are far more difficult to 
quantify than other benefits, and they have received far less 
research attention than the harms of marijuana use’ (p. 11). 
The authors conclude that policy decisions must be made in 
a ‘fog of uncertainties’:
There is no recipe for marijuana legalization, nor are there 
working models of established fully legal marijuana markets. 
It must be expected that any initial set of choices will need 
to be reconsidered in the light of experience, new knowledge, 
and changing conditions, including federal policy and the 
policies in neighboring states. That puts a premium on 
flexibility; the policy should not be frozen into its initial 
design. (p. 12)
http://www.rand.org/content/dam/rand/pubs/
perspectives/PE100/PE149/RAND_PE149.pdf 
(Compiled by Brigid Pike)
Adolescents and parental substance 
misuse 
Keeley and colleagues1 recently published the results of 
their analysis of data collected in 26 schools in Cork and 
Kerry from a cohort of 2,716 adolescents aged 15–17 years. 
The data were collected using the ‘Lifestyle and Coping 
Questionnaire’ designed specifically for the Child and 
Adolescent Self-harm in Europe (CASE) study, which contains 
questions on a number of psychological domains including 
drug and alcohol use. Two questions were added to the 
standard questionnaire regarding parental substance misuse: 
‘Has your mother had problems with alcohol/drugs?’ and 
‘Has your father had problems with alcohol/drugs?’
Alcohol and drug use among adolescents 
Eighty-three per cent of respondents (n=2,242) reported 
having consumed alcohol at least once, with no significant 
difference between boys and girls. Fifty per cent reported 
consuming 1–5 alcohol drinks in a typical week; 37% 
reported being really drunk on 1–3 occasions in the past 
month and 31% recalled being really drunk 1–3 times in the 
past year. Interestingly, and despite the high overall lifetime 
prevalence of 83%, over half the cohort (56.6%) reported 
that they had never been really drunk in the past month and 
just over a third (35%) had never been really drunk in the 
past year. 
Less than a third of the cohort (31%) reported using an 
illicit drug at least once; less than a quarter (23.3%) in the 
last month and less than a third (32.9%) in the last year. 
Cannabis was the illicit drug most commonly used by both 
boys and girls; 93% of those who had used an illicit drug in 
the last month reported having used cannabis. 
Substance misuse by parents and by their children
The authors reported an association between parental 
substance misuse and adolescent substance misuse. The 
magnitude of the risk was marginally higher if the parent 
misusing substances was the mother, and higher again if 
both parents were misusing substances. The association 
between parental substance misuse and an increased risk of 
adolescent substance misuse remains after adjusting for a 
number of other variables. However, it must be noted that 
from a relatively large cohort of adolescents, only 3.5% 
reported that their mother misused substances and 1.4% 
reported that both parents misused substances. Indeed, 
almost 89.6% of the cohort reported that their parents did 
not misuse substances. 
The authors acknowledged the limitations of the study. 
The two questions on parental substance misuse did not 
distinguish between drugs and alcohol misuse and did not 
establish if the misuse was on-going or not. They went on to 
say, ‘Despite these limitations, the paper adds information on 
the role parental misuse might have on young people’s risk 
of developing addiction in an Irish context…’ (p. 7).
Discussion
This study showed that alcohol consumption on at least 
one occasion among this cohort of 15–17-year-olds was 
the norm. However, the frequency and level of alcohol 
consumption varied considerably. The study also showed 
that among the same cohort, the use of illicit drugs was not 
the norm, with over two thirds reporting not using illicit 
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Parental substance misuse (continued)
drugs. Among the third who did report using illicit drugs, the 
vast majority (93.8%) used cannabis. 
It is important that young people are presented with data 
from research studies as part of prevention interventions. 
For example, the majority of the young people in the cohort 
studied by Kelley and colleagues did not use illicit drugs. 
Challenges to the perception that substance use is the norm 
among others can be delivered as part of the Social Norms 
programme.3 
(Martin Keane) 
1. Keeley HS, Mongwa T and Corcoran P (2015) The 
association between parental and adolescent substance 
misuse: findings from the Irish CASE study Irish Journal 
of Psychological Medicine, early online http://www.
drugsandalcohol.ie/23244/ 
2. Murphy KD, Byrne S, Sahm LJ, Lambert S and McCarthy S 
(2014) Use of addiction treatment services by Irish youth: 
does place of residence matter? Rural and Remote Health 
(14): 2735 http://www.drugsandalcohol.ie/22461/ 
3. Keane M (2011) The social norms approach to tackling 
substance use Drugnet Ireland (38): 16–17 http://www.
drugsandalcohol.ie/15646/ 
National Poisons Information Centre 
annual report 2013
According to its annual report,1 the National Poisons 
Information Centre (NPIC) received 9,816 enquiries in 2013. 
Of these, 9,520 (97%) were about human poisonings. The 
remaining calls concerned poisonings in animals (0.7%) 
and non-emergency requests for information (2.3%). Calls 
were evenly distributed over the week, with an average of 
27 calls every day and the busiest time being between 6pm 
and 9pm.
The most frequent enquiries were from general practitioners/
primary care personnel (39.7%), hospitals (27%) and 
members of the public (27.8%). The other sources of 
enquiries were community pharmacists, nursing/care homes, 
ambulance and emergency services, veterinary practices and 
schools. Calls from members of the public in 2013 increased 
by 7% over the previous year.
Over half (56%) of the enquiries about cases of poisoning 
in humans concerned children under 10 years of age, with 
boys outnumbering girls. There were 2,166 (23%) enquiries 
about adults (aged 20 years or over), with women being 
the subject of just over half of all enquiries and over half the 
enquiries (52%) being about intentional self-poisoning or 
recreational abuse. Most poisonings (93%) occurred in the 
home or domestic setting.
Drugs (pharmaceuticals and drugs of abuse), industrial 
chemicals and household products were the most common 
agents involved in human cases of poisoning. As in previous 
years, the most common enquiry concerned substances 
containing paracetamol. The second most common agent 
was ibuprofen. Cannabis was the most common drug of 
abuse discussed with the NPIC, followed by cocaine  
and heroin. 
Of the 191 enquiries relating to liquid detergent capsules, 
93% concerned children aged less than 5 years. The NPIC 
liaises with the Health and Safety Authority (HSA) regarding 
the increasing number of poisoning incidents involving 
liquid laundry detergent capsules. Actions taken to decrease 
the incidence of accidental poisoning from liquid laundry 
detergent capsules in young children include changes to the 
packaging and labelling of liquid detergent capsule products 
and consumer campaigns to raise awareness about safe use 
and storage.
Only a small proportion of enquires (271, 2.8%) required 
follow-up. Although most cases recovered completely, 17 
cases suffered adverse effects, a further 12 died, and the 
outcome of 23 cases could not be determined. Drugs were 
implicated in eight of the fatal cases, and five of these 
involved drugs of abuse. 
(Ena Lynn) 
1. National Poisons Information Centre of Ireland (2014) 
Annual report 2013 Dublin: Poisons Information Centre of 
Ireland. http://www.drugsandalcohol.ie/23241/ 
Overdose 'hot spots' in Dublin
Globally, opioids are one of the main causes of death among 
problem drug users. In countries with a high prevalence 
of heroin use, including Ireland, opiates are implicated in 
the majority of overdoses. Acute opioid overdoses impose 
a considerable burden on frontline health services such 
as ambulances and emergency departments. While the 
impact of environmental factors (e.g. deprivation, physical 
characteristics of area, allocation of health services) on the 
incidence of overdose has not been widely studied, historical 
data show that overdoses and associated fatalities are more 
common in areas where there is increased drug use, drug 
dealing and other drug-related activities, and addiction 
services have been set up in these areas.  
A recent study looked at opioid overdoses in Dublin  
in order to understand more fully the risk factors involved, 
to help reduce the associated mortality and morbidity 
and to improve the response to such incidents.1 The study 
had two aims: to establish a baseline incidence of all new 
overdoses that Dublin ambulances attend, and to look at the 
relationship between geographical location of overdoses, 
deprivation and location of methadone clinics. See Table 1 
for a summary of the findings with regard to the  
overdose cases. 
There are two ambulance services in Dublin: the Dublin Fire 
Brigade (DFB), and the National Ambulance Service (NAS) 
operated by the Health Service Executive (HSE). Ambulance 
staff enter data on each individual that they attend on a 
12
drugnet 
Ireland
Overdose ‘hot spots’ (continued)
patient care report (PCR). The PCR is a paper-based record 
of the pre-hospital care given by ambulance staff/first 
responders. All PCRs for a 12-month period in 2012–2013 
were reviewed prospectively to identify opioid overdoses. All 
relevant data were extracted: clinical presentation; clinical 
care provided; administration of naloxone; response to 
naloxone; whether the patient was taken to hospital; and 
death, if confirmed by ambulance staff on scene. Follow-up 
data on patients who were taken to emergency departments 
were not collected for this study.
The locations of overdoses were categorised as ‘street’, 
‘residential’ (house/hotel) or ‘service’ (homeless shelter, 
treatment centre, hospital, shop, pub, Garda station). DFB 
personnel assigned geographic co-ordinates for the location 
of every overdose attended. These data were not available for 
attendances by the NAS.
Over the study period, ambulances attended 469 opioid 
overdoses. This gives an overdose incidence of 4.9 cases per 
1,000 cases per year. 
The relationship between overdose and deprivation was 
examined using the Pobal-Haase-Pratschke Deprivation 
Index and pre-existing Small Area (SA) boundaries.3 The 
Deprivation Index is a composite score ‘measuring the 
relative affluence or disadvantage of a particular geographic 
area’. The score ranges from -40 (most disadvantaged) 
to +40 (most affluent). Each overdose was mapped to its 
corresponding SA. There were some statistically significant 
differences found between:
 ■ the number of overdoses and level of area affluence, with 
a greater number of overdoses occurring in less affluent 
areas, and
 ■ the locations where overdoses occurred, with overdoses 
occurring in residential locations having a lower 
deprivation score than overdoses occurring in street 
locations.
The study also looked at the location of methadone  
clinics in relation to overdoses. This showed that most 
overdoses occurred within a 1,000-metre radius of certain 
methadone clinics. 
The authors identified some limitations to the study. PCR 
forms were not always reliable (they were hand-written 
under stressful circumstances and often involved difficult 
decisions) and data could not be validated. Geo-data were 
not available for NAS PCRs.
The results of the study highlight several issues which can 
help inform decisions about preventing overdose deaths. 
Dublin ambulance services attended an opioid overdose 
almost daily; the majority occurred in Dublin city centre, 
on the street, during the day and near certain methadone 
clinics; street overdoses were more likely to occur in the 
city centre and on the quays, while residential overdoses 
were more likely to occur in the suburbs. Clinical findings 
showed patients had low mean GCS scores pre-intervention, 
meaning that many patients were unconscious. However, the 
mean GCS scores post-intervention showed improvement, 
indicating the effectiveness of the intervention given by 
the ambulance staff. However, the results also showed that 
the GCS scores of 25% of patients did not improve after 
administration of naloxone. 
Despite international research indicating that overdose 
prevention and naloxone distribution programmes can help 
to reduce overdose deaths, not many countries provide such 
programmes.4 The authors stated that the results point to the 
need for such a programme, based in the community,  
in Ireland. 
(Suzi Lyons)
1. Klimas J, O’Reilly M, Egan M, Tobin H and Bury G (2014) 
Urban overdose hotspots: a 12-month prospective study 
in Dublin ambulance services. The American Journal of 
Emergency Medicine, accepted manuscript (in press). http://
www.drugsandalcohol.ie/22440/ 
2. The Glasgow Coma Scale (GCS) aims to provide an 
indication of the neurological state of a person. The scores 
range from 3 (worst) to 15 (best). A score of less than 8 is 
considered severe. The total score is the sum of the scores 
in three categories: eye opening, verbal response and motor 
response. 
3. Small area (SA) boundaries are subdivisions of pre-existing 
electoral districts created by the Central Statistics Office. 
www.cso.ie/census 
4. Lyons S (2014) Preventing opiate-related deaths in Ireland: 
the naloxone demonstration project Drugnet Ireland (49): 
13. http://www.drugsandalcohol.ie/21677/ 
Characteristics 
of patients 
who overdosed
•	 80% male
•	 Mean age 33 years
•	 Evidence of opiate use observed  
in 89%
•	 Evidence of use of other drugs, 
mainly alcohol, observed in 28% 
•	 45% of patients attended to on  
the street
•	 38% attended to in a residential 
location
•	 70% attended to during the day
•	 27% repeat overdoses
Data on clinical 
presentation 
of the patient
•	 39% unresponsive
•	 10% in respiratory arrest
•	 12% with respiratory depression
•	 4% in cardiac arrest.
•	 Mean GCS score:2 
o pre-intervention 7.2
o post-intervention 12.3
•	 3% confirmed dead at the scene
Type of 
intervention 
provided
•	 76% administered naloxone:
o 66% given naloxone 
intramuscularly
o mean number of  
doses 1.5
•	 22% given assisted ventilation
•	 60% administered oxygen
•	 89% transported to hospital
Geographic 
location of 
overdoses 
•	 86% Dublin city centre
•	 6% South Dublin
•	 5% Fingal
•	 1% Dun Laoghaire
Table 1: Profile of overdose cases attended by ambulance 
services, Dublin 2012–2013
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‘Alcohol – starting the conversation and 
finding solutions’
On Thursday 11 December 2014 the D12 Local Drugs and 
Alcohol Task Force (LDATF) organised a consultation seminar 
on alcohol in order to begin a discussion around problem 
alcohol use in the area and possible solutions.1 
The morning started with introductions by Susan Sargent 
(chair of the D12 LDATF) and Aoife Fitzgerald (co-ordinator 
of the D12 LDATF). Three guest speakers then addressed 
the seminar: Suzanne Costello (Alcohol Action Ireland), 
who gave the national perspective on alcohol; Dr Suzi 
Lyons (Health Research Board), who presented local alcohol 
data from the National Drug Treatment Reporting System 
(NDTRS); and Hugh Greaves (Ballymun LDATF), who spoke 
about the approach the Ballymun LDATF has taken to 
dealing with problem alcohol use. 
Hugh Greaves described how Ballymun LDATF took a public 
health-based approach to developing their strategy, using a 
community mobilisation model. The process included round-
table events and a large number of stakeholders. 
After the presentations, the seminar participants  
broke into four workshops, which reached the following 
broad conclusions:
 ■ Treatment and rehabilitation: The key priorities identified 
by this workshop included the need for additional 
training, for example SAOR (screening and brief 
intervention for people with hazardous/harmful alcohol 
use), and the need to encourage population-level 
interventions to reduce harmful drinking.
 ■ Young people and alcohol: The need for outreach, 
education and alternative activities was highlighted by 
this workshop.
 ■ Education, prevention and health promotion: This 
workshop stressed the importance of schools and 
teachers in educating young people and raising 
awareness, the need for greater awareness of problem 
alcohol use in the community, and the need to involve  
all stakeholders. 
 ■ The effect of alcohol on families and children: The 
importance of role models, the need for a public 
campaign on the impact of alcohol on children and the 
need for additional supports for families as a whole were 
all emphasised by this workshop.
On foot of the outcomes of the consultation seminar, the 
D12 LDATF committed to work over the following months 
to develop a strategy to address alcohol-related harm in the 
D12 area, using a community mobilisation model.2 
(Suzi Lyons)
1. To access a copy of all the presentations and full reports 
from the workshops, see http://www.drugsandalcohol.
ie/23377/ 
2. For further information on the work of the D12 LDATF and 
the Ballymun LDATF, visit http://www.d12ldtf.ie and/or 
http://www.ballymunlocaldrugstaskforce.ie respectively.
Sentencing in drug cases
A recent study conducted by the Irish Sentencing 
Information System (ISIS)1 examines the sentencing practices 
of the Irish courts in relation to the offences of possession 
or importation of controlled drugs for the purpose of sale or 
supply.2 There are four such offences which are covered by 
the study:
 ■ possession of controlled drugs for unlawful sale or supply 
(s. 15 of the Misuse of Drugs Act 1977, as amended),
 ■ possession of controlled drugs (valued at €13,000 or 
more) for unlawful sale or supply (s. 15A of the Misuse of 
Drugs Act 1977, as amended),
 ■ importation of controlled drugs for unlawful sale or 
supply (several provisions found in the Customs Acts, 
Misuse of Drugs Acts 1977–1984, as amended, and the 
Misuse of Drugs Regulations 1988), and
 ■ importation of controlled drugs (valued at €13,000 or 
more) for unlawful sale or supply (s. 15B of the Misuse of 
Drugs Act 1977, as amended).
Convictions under s.15A or s.15B of the Misuse of Drugs 
Act 1977 attract a ‘basic presumptive sentence’ of 10 years 
or more. A sentencing court may, however, impose a lower 
sentence where there are mitigating factors that amount to 
‘exceptional and specific circumstances’, which would render 
the imposition of a sentence of 10 years or more ‘unjust in all 
the circumstances’.3 
Part I of the report analyses the legislative basis for these 
drug trafficking offences and the reserved judgements 
of the superior courts. Part II examines the application of 
sentencing principles in relation to the ‘basic presumptive 
sentence’ provided for in s. 15A and s. 15B. Part III examines 
79 judicial decisions involving 81 offenders before the Court 
of Criminal Appeal between 2009 and 2012. Twenty of these 
judgements relate to ordinary offences and 59 to offences 
carrying the presumptive sentence.
The case law analysed shows that ‘in the majority of s. 
15A and s. 15B sentences (67% of those surveyed), the 
presumptive minimum sentence of 10 years imprisonment 
or more is not imposed by the courts despite the fact 
that this sentence is popularly described as a “mandatory 
minimum” ’ (p. 6). However, this does not mean that 
the courts are disregarding the presumptive minimum 
sentencing provisions. As the author explains, ‘the Court 
of Criminal Appeal has repeatedly emphasised that the 
upper parameters of these offences are properly defined 
by reference to the maximum penalty of life imprisonment 
and not, as is often the case, to the presumptive mandatory 
minimum of 10 years’ (p. 6). This is the case at least with 
regard to possession for supply offences. With regard to 
importation offences, the author concludes that the statutory 
framework ‘is less coherent’ (p. 6). This is due to the fact that 
the ordinary offence exists under legislative provisions which 
provide different maximum penalties, ‘one of which carries 
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a maximum penalty of 14 years imprisonment and the other 
carries a maximum sentence of life imprisonment’ (p. 6).
This anomaly exists primarily for historical reasons that can 
be traced back to the emergence of the heroin ‘epidemic’ 
in Dublin in the early 1980s. Prior to the introduction of the 
maximum sentence of life imprisonment in 1984, the upper 
limit of 14 years applied to importation and possession for 
sale and supply offences. Such a maximum sentence was 
imposed in The People (Director of Public Prosecutions) v. L.D., 
the initials standing for Larry Dunne, a leading member 
of the family largely credited with introducing heroin to 
Dublin at that time.4 In the period between the commission 
of the offence, and the date of sentencing, the legislature 
had increased the maximum penalty. In passing sentence, 
McMahon J. stated that the major players involved in drug 
trafficking could in future expect life imprisonment. As the 
ISIS report shows, however, to date no convicted person 
has received the maximum sentence of life imprisonment. 
As a consequence, as the author points out, ‘It is sometimes 
therefore popularly espoused that custodial sentences 
imposed are too short or that disparity exists from one 
sentence to the next’ (p. 7). Such disparity is apparent in the 
following cases examined by the author of the ISIS report:
… one offender found with €300,500 of cannabis and 
cocaine was sentenced to the presumptive minimum of 10 
years while another found with €329,301 of cocaine  
received a wholly suspended sentence; a man found with 
€43,000 of cocaine received a 1.5 year custodial sentence 
while another man found with €287,050 of cannabis 
received 4 years. (p. 7)
The ISIS report finds that in supply offences involving drugs 
valued at €13,000 or more, the value is the most important 
factor in determining the sentence. However, this is not the 
only factor considered, as sentences differ relative to the 
circumstances of individual cases and individual offenders. 
This approach is regarded as consistent with general 
sentencing principles. 
The analysis of cases provided in the report shows that there 
are four primary factors featuring in the construction of 
sentences for drug trafficking offences:
 ■ quantity or value of the controlled drug or drugs,
 ■ type of controlled drug or drugs,
 ■ role of the offender, and
 ■ condition of the offender (p. 7).
The Law Reform Commission (LRC), an independent 
statutory body established to keep the law under review and 
to make proposals for reform, has recently recommended 
that the presumptive sentencing regime for drug offences  
be repealed.3
(Johnny Connolly)
1. ISIS was established by the Board of the Courts Service as a 
computerised information system on sentences and other 
penalties imposed for offences in criminal proceedings. 
ISIS enables a judge, by entering relevant criteria, to access 
information on the range of sentences and other penalties 
which have been imposed for particular types of offence in 
previous cases. http://www.irishsentencing.ie/ 
2. Mackey K (2014) Analysis of sentencing for possession 
or importation of drugs for sale or supply Dublin: Irish 
Sentencing Information System
3. For a detailed account of the legislation and 
recommendations for change, see Law Reform Commission 
(2013) Report: mandatory sentences. LRC 108–2013 Dublin: 
Law Reform Commission
4. For an account of this period, see Flynn S and Yeates P 
(1985) Smack: the criminal drugs racket in Ireland Dublin: Gill 
& Macmillan
Dr Sarah Morton (centre), School of Applied Social Science, University College Dublin, Dr Laura O’Reilly and Karl O’Brien, both Ballymun 
Youth Action Project, authors of Boxing clever: exploring the impact of a substance use rehabilitation programme, at the launch of the 
report in February. The report was prepared from an evaluation of BYAP’s Boxing Clever programme in 2013/2014 which was undertaken in 
partnership with the UCD School of Applied Social Science Community Partnership Drugs Programme. This report will be covered in the issue 
54 of Drugnet Ireland.
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Ana Liffey strategic plan 2015–2017
Unlike Ana Liffey Drug Project's (ALDP's) previous strategic 
plan for 2012–2014, which was developed during a 
recession, its new strategic plan ‘resides in the more positive 
context of economic recovery’. So states Eddie Matthews, 
chair of ALDP, in his foreword to the new strategic plan 
for 2015–2017.1 ALDP is now introducing creative new 
approaches to targeting drug-related harm in Ireland, and 
seeking support specifically for:
 ■ low-threshold residential stabilisation services, and
 ■ medically-supervised injecting centres.
Ana Liffey, which works directly with over 2,500 people 
affected by addiction problems in Ireland every year, is 
seeking support to provide a suitable premises for a ‘low-
threshold residential stabilisation’ service. This will provide 
treatment for drug users with multiple and complex needs 
which require immediate specialist support.
Tony Duffin, director of ALDP, says that with a suitable 
property, Ana Liffey could accommodate up to 20 people at 
a time on a pilot project to help them to stabilise, to stay off 
the streets as well as reducing the demands on other health 
services.  The operating costs for such a service would be 
approximately €1.5 million. He states that research shows 
that every euro spent on treatment can save countries up 
to €2.50 in other costs, through public health benefits and 
cutting crime.2
In addition to the stabilisation service, Ana Liffey is also 
seeking to establish in Dublin a medically-supervised 
injecting centre where an addicted person can inject 
themselves safely and away from the public’s gaze.3 
According to Duffin, ‘They [medically-supervised injecting 
centres] are a very successful intervention, with over 90 
centres in countries throughout the world. Not only do they 
contribute to reducing public injecting and unsafe disposal, 
they also help people attending to tackle their addictions 
through dedicated access to treatment programmes.’
 
Since 1982 ALDP has provided a ‘low-threshold harm 
reduction’ service to individuals who are experiencing 
problematic substance use and to their families. In recent 
years, it has established services in the Midlands and the 
Mid-West and it plans to expand its services to reach as 
wide a client base as possible across the country. According 
to ALDP, an average of one person dies from overdose in 
Ireland every day and people are using multiple substances 
in every town and city in Ireland. 
In ‘targeting harm’, ALDP’s rationale is that Ireland has 
limited resources to deal with problem drug use and needs 
to target the resources it does have towards evidence-
informed interventions which have been shown to reduce 
the harm drug use causes to individuals, families and 
communities. Duffin comments, ‘Drug use has changed. 
There is more and more poly-drug use and an increasing 
number of complex cases. We need to accept, as a society, 
that it is not realistic to expect to be able to stop all drugs 
entering the country, or to be able to eliminate problem 
drug use.’ 
Noting that Ana Liffey provides valuable and helpful services 
to those who use drugs problematically, to their families and 
to the broader communities, chair Eddie Matthews sums up 
Ana Liffey’s approach:
[We work] through the prism of pragmatism. We neither 
condone nor condemn drug use. We are non-judgmental 
and client-centred, believing in the potential of every 
individual. We believe in the value of harm reduction. Our 
strategic plan includes a strong focus on working with 
government departments, NGOs, universities and other 
stakeholders to develop effective programmes, necessary 
legislation and sufficient funding to tackle drug addiction in 
this country.
1. Ana Liffey Drug Project (2014) Targeting harm: the strategic 
plan of the Ana Liffey Drug Project 2015–2017. Dublin: Ana 
Liffey Drug Project. http://www.drugsandalcohol.ie/23173/ 
2. In October 2014 Public Health England, an executive 
agency of the UK's Department of Health, uploaded a 
document on its home page entitled Alcohol and drugs 
prevention, treatment and recovery: why invest? Among the 
benefits of investment, the document states that every £1 
spent on drug treatment saves £2.50 on costs to society, 
through preventing an estimated 4.9m crimes every year 
and an estimated £960m costs to the public, businesses, 
criminal justice and the NHS (p. 27). http://www.nta.nhs.
uk/uploads/why-invest-2014-alcohol-and-drugs.pdf The 
National Documentation Centre on Drug Use located this 
source.
3. According to a report posted on Talking Drugs ( http://
www.talkingdrugs.org/ ) on 26 February 2015, and 
reported on DrugScope Daily on 27 February 2015, 
the ALDP is working in collaboration with the Voluntary 
Assistance Scheme at the Bar Council of Ireland on 
legislation to make the opening of a medically-supervised 
injecting centre in Dublin possible. It is currently illegal 
under the Misuse of Drugs Act 1977. 
Mr Tony Duffin, director of ALDP, and Mr Joe Duffy at the launch 
of the Ana Liffey Drug Project strategic plan 2015–2017 in City 
Hall in December.
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HSE National Service Plan 2015
The HSE’s National Service Plan 2015 (NSP), approved 
by the government in December 2014, sets out the HSE’s 
priorities and targets for tackling tobacco and alcohol 
misuse, and drug addiction, in 2015.1 The HSE’s divisional 
plans, on which the NSP is based, list specific operational 
tasks with timeframes, and a ‘balanced scorecard’ of 
performance targets. The following account draws on both 
the aggregated NSP and the more detailed operational plans 
for the Health and Well-Being and the Primary Care divisions, 
which share responsibility for tobacco, alcohol misuse and 
addiction services.
Tobacco and alcohol misuse
The Health and Well-Being Division will focus on the ‘key 
modifiable risk factors for chronic disease and ill-health’ 
including tobacco and alcohol misuse.2 The Division is 
preparing for the roll-out of the relevant provisions in both 
tobacco and alcohol legislation in consultation with the 
Department of Health and in line with existing resources. Key 
actions and performance targets for 2015 are as follows: 
Tobacco Free Ireland 3 
 ■ Implement priority actions, with a particular focus on the 
continued roll-out of the tobacco free campus policy in 
primary care (100%); mental health (100% approved 
centres and 25% residential services); disability and 
social care residential services (disability [25%] and older 
persons [20%]); and Tusla sites (100%).
 ■ Reduce tobacco usage in the general population 
by undertaking training, intervention, surveillance, 
evaluation, enforcement of legislation and social 
marketing activities. Targets for 2015 include 1,500 
frontline healthcare staff trained in brief intervention 
for smoking cessation; 9,000 smokers receive intensive 
cessation support; and 2,450 smokers who enter a 
cessation programme quit at one month.
Performance Target: 100% health care centres tobacco-free
National Substance Misuse Strategy4
 ■ Further develop a co-ordinated approach to prevention 
and education interventions in alcohol between all 
stakeholders including 3rd-level institutions. Target is to 
have a national accreditation system in place in a number 
of 3rd-level colleges.
 ■ Support pilot community mobilisation alcohol initiatives 
in five drugs task force areas (North Inner City, Tallaght, 
Dun Laoghaire/Rathdown, North West and South) 
through grant agreement with Alcohol Forum.5 Five local 
alcohol action plans developed by end of year.
Community Oncology Cancer Control Programme 
(COCCP)
In the Primary Care Division of the HSE, the COCCP has 
a commitment to ‘implement a national standardised 
algorithm for the treatment of tobacco addiction’ by the end 
of 2015.6
Addiction services
In the Primary Care Division of the HSE, a key priority for 
the Social Inclusion Services is to ‘achieve improved health 
outcomes for people with addiction issues’.6 Seven key 
actions and associated tasks have been identified for 2015:
1. Progress the integration of drugs task force projects 
and developments within the wider addiction services 
in line with objectives in the NDS7
 ■ Ensure that each local and regional drug and alcohol task 
force (DATF) project is governed by the HSE grant aid 
agreement/service arrangement for 2015.
 ■ Additional funding of €1.023m has been notified to 
support measures to tackle substance misuse. This 
funding will support community and voluntary groups 
or other relevant bodies to undertake one-off prevention 
initiatives in line with the National Substance Misuse 
Strategy.
 ■ Assist projects to participate in planning and reporting in 
line with the monitoring tool developed by the National 
Addiction Advisory Governance Group, within the 
Section 39 Governance Framework.
 ■ Ensure that funded organisations:
•	 support and promote the aims and objectives of 
the NDS to significantly reduce the harm caused 
to individuals and society by the misuse of drugs. 
Their annual plans must be linked to both the 
national strategic actions and local drug strategy/
implementation plans;
•	 provide the HRB with data on each service user 
entering and existing service in compliance with the 
National Drug Treatment Reporting System (NDTRS);
•	 engage with a Quality Standards Framework such 
as QuADS through the Quality Standards Support 
Project; and
•	 implement case management process as guided by 
the National Drugs Rehabilitation Framework.
2. Implement priority actions from the NDS (Programme 
for Government Primary Care Funds €2.1m) – 
implement the clinical governance framework for 
addiction treatment and rehabilitation services
 ■ Develop integrated drug and alcohol services in line with 
the NDS and the National Substance Misuse Strategy, 
which provide drug-free and harm reduction approaches 
for problem substance users, and
•	 facilitate problem substance users to engage with, and 
avail of, such services;
•	 ensure that each patient has an appointed key worker 
and a clearly documented care plan that is subject to 
a regular review and update;
•	 measure transfers from HSE clinics and level-2 GPs to 
level-1 GPs; and 
•	 carry out a client satisfaction survey of all the 
addiction services.
 ■ Participate in the European Union Reducing Alcohol 
Related Harm (RARHA) Project.
 ■ Develop national guidelines for alcohol consumption to 
reduce health risks from drinking. 
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HSE NSP 2015 (continued)
 ■ Implement a naloxone demonstration project to assess 
and evaluate its suitability and impact (in line with NDS 
Action 40).
 ■ Develop a clinical and organisational governance 
framework (in line with NDS Action 45).
 ■ Finalise, launch and maintain an on-line directory 
of drug and alcohol services and specialist drugs 
and alcohol treatment programmes (in line with the 
recommendations from the Working Group on Drugs 
Rehabilitation, Action 32).
 ■ Screening and brief intervention (SBI): 
•	 Roll out SAOR (Support, Ask and Assess, Offer 
Assistance and Refer) screening and brief intervention 
training for alcohol and problem substance use 
within tier 1 and tier 2 services (25 SAOR training 
programmes to 300 staff and 3 train-the-trainer 
programmes will be delivered nationally) in 
partnership with Health Promotion and Improvement 
and the National Addiction Training Programme.
•	 Develop and implement an SBI implementation plan 
to support the roll-out of national SBI protocol.
 ■ Hidden harm:
•	 Finalise a strategic statement regarding hidden harm 
together with Tusla and drug and alcohol services. 
This statement will guide two pilot sites (north-west 
and Midlands) to ensure early intervention.
•	 Commission training on hidden harm on behalf of 
Tusla and drug and alcohol services staff.
•	 Participate on the North-South Alcohol Policy 
Advisory Group.
 ■ National Addiction Training Programme:
•	 Finalise a training needs analysis and workforce 
development plan in line with NDS Action 47.
•	 Co-ordinate the provision of training within the 
substance misuse framework, i.e. Addiction Training 
Programme, in line with NDS Action 47.
3. Implement the outstanding prioritised 
recommendations of the Opioid Treatment Protocol, 
including the development of an audit process across 
the full range of drug services. This will incorporate 
person-centred care planning through the Drug 
Rehabilitation Framework and increase opioid 
substitution treatment (OST) patient numbers
 ■ Develop an audit process across the full range of 
drug services that incorporates person-centred care 
planning through the Rehabilitation Framework, in line 
with the introduction of the Opioid Treatment Protocol 
recommendation 2.3.
 ■ Increase the maximum number of OST patients from 
15 to 25 for level 1 prescribers, and in exceptional 
circumstances from 35 to 50 for level 2 prescribers, in 
line with Opioid Treatment Protocol recommendations 3.4 
and 3.5.
 ■ Performance targets:
•	 No. of clients in receipt of OST (outside prisons): 
9,400
•	 No. of clients in receipt of OST (in prisons): 490 
•	 % of substance misusers over 18 years for whom 
treatment has commenced within one calendar 
month of assessment: 100%
•	 % of substance misusers under 18 years for whom 
treatment has commenced within one week of 
assessment: 100%
4. Implement referral and assessment for residential 
services using a shared assessment tool agreed 
between the HSE and service providers in line with the 
Drug Rehabilitation Framework
 ■ Develop a shared assessment tool between HSE and Tier 
4 service providers in line with the Drugs Rehabilitation 
Framework and National Protocols and Common 
Assessment Tools.
5. Implement the findings of the evaluation of the 
Pharmacy Needle Exchange Programme (PNEX)
 ■ Increase the level of knowledge of pharmacies in relation 
to harm reduction as per the PNEX.
 ■ Provide training for PNEX staff to reflect the wider range 
of service provision.
 ■ Strengthen integrated care pathways and referral 
pathways for patients. 
 ■ Enhance advice and information giving on sexual 
health including appropriate referral for BBV testing and 
increased condom distribution.
 ■ Performance target: 
•	 Number of unique individuals attending pharmacy 
needle exchange: 1,200
6. Implement prioritised recommendations of the Tier 4 
Report (Residential Addiction Services)
 ■ Develop a Clinical Audit team and draw up an approved 
list of residential services based upon adherence to 
best practice quality standards in relation to staff 
competencies and clinical operations.
7. Develop joint protocols for integrated care planning 
between mental health services and drug and alcohol 
services
 ■ Develop joint protocols between mental health and 
drug and alcohol services for patients with severe 
mental illness and substance misuse problems, in 
line with National Substance Misuse Strategy 2011, 
Recommendation 10, and NDS Action 33).
Monitoring progress
Each month the HSE issues a Performance Assurance Report 
(PAR), analysing key performance data year-to-date against 
the performance targets set in the annual NSP. It is based 
on metadata, which are also published by the HSE. These 
reports are available at http://www.hse.ie/eng/services/
publications/corporate/performanceassurancereports/ 
1. Health Service Executive (2014) National service plan 2015. 
http://www.drugsandalcohol.ie/23052/ 
2. Health Service Executive (2014) Health and well-being 
operational plan 2015. Dublin: HSE. http://www.
drugsandalcohol.ie/23275/ 
3. Tobacco Policy Review Group (2013) Tobacco free 
Ireland. Dublin: Department of Health. http://www.
drugsandalcohol.ie/20655/ 
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HSE NSP 2015 (continued)
Youth programmes reviewed
The Department of Children and Youth Affairs (DCYA) 
has published its review of three youth programmes: the 
Special Projects for Youth (SPY), the Young People’s Facilities 
and Services Fund (YPFSF) and the Local Drugs Task Force 
(LDTF) projects.1 The review was undertaken as a value-for-
money and policy review (VFMPR) to examine the efficiency 
and effectiveness of the three programmes. This article 
summarises the key messages from the review.
Review method and rationale 
The reviewers collected data via site-based interviews with 
front-line staff and young people, interviews with the Youth 
Affairs Unit of the DCYA, a survey of all youth programme 
providers, an analysis of high-level statistical data, a review of 
administrative data and a literature review. 
The three programmes under review target ‘at-risk’ young 
people who are disadvantaged in different ways, with some 
experiencing multiple disadvantages. The programmes 
generally target 10–21-year-olds in areas characterised 
by problem drug use, educational disadvantage, criminal 
activity, unemployment and homelessness. The review notes 
that there are indications in the available national data that, 
overall, drug use, youth crime and youth homelessness have 
declined while unemployment and poverty rates among 
young people of working age have increased. The review 
points out that students attending ‘DEIS schools’2 continue 
to experience higher levels of non-attendance, suspensions 
and expulsions compared to students in non-DEIS schools 
and the gap is widening. Furthermore, the review notes 
that young people with lower levels of education are more 
likely to be unemployed. Based on these factors and the 
expected increase in the overall youth population, the review 
suggests that ‘…there remains a valid rationale for the 
provision of youth programmes for young people who are 
disadvantaged…’ (p. 67).
Governance arrangements
Based on an analysis of the data collected, the authors of 
the review question the capacity of the current governance 
arrangements to adequately fulfil their purpose which 
is defined as the ‘…means to effectively and efficiently 
implement intended policy objectives within established 
rules...’ (p. 51). In particular, the review highlights the poor 
quality of data submitted by programme providers, which 
made it difficult for those with governance responsibilities to 
make judgements regarding the efficiency and effectiveness 
of the programmes. 
Efficiency
The review notes that efforts to undertake a comprehensive 
analysis of the efficiency of the programmes were hampered 
by reliance on a small sample of service providers to estimate 
salary costs, staff numbers, average daily and annual 
participant numbers and unit costs. The review reports 
that total expenditure on the programmes declined by 
approximately 16% between 2010 and 2012. 
Effectiveness
One of the terms of reference of the review was to examine 
the extent to which the youth programmes’ objectives had 
been achieved and to comment on their effectiveness. From 
the review of the international literature, seven ‘potent 
programme outcomes’ were identified: 
 ■ communication skills,
 ■ confidence and agency,
 ■ planning and problem-solving,
 ■ relationships, 
 ■ creativity and imagination, 
 ■ resilience and determination, and 
 ■ emotional intelligence. 
The evidence suggests that these outcomes are associated 
with improvements for the young people targeted by the 
programmes, e.g. getting a job, completing college or giving 
up using drugs.
These seven outcomes were used to retrospectively examine 
local practice in 13 sample sites, with data being collected 
via the survey to programme providers, interviews with front-
line staff and young people and a review of administrative 
data related to the programmes. 
The review found ‘evidence of “presence” of these seven 
mechanisms that were (a) intentionally and consciously 
applied by professionals in pursuit of beneficial outcomes, 
and (b) experienced by young people’ (p. 111). However, 
the authors comment that this evidence from selected sites 
fell far short of confirming that outcome-focused practice is 
being routinely adopted. 
Continued relevance
The review reports that there is a ‘fit’ between the three 
targeted youth programmes and current DYCA strategy. 
The authors conclude that ‘these programmes can make 
a difference [and] can provide a significant contribution 
to improving outcomes for the young people involved 
and should be considered for public funding…’ (p. 126). 
However, they go on to say that the ‘programmes and 
performance governance arrangements require significant 
reform… [relating] to the development of a robust 
performance evaluation framework to inform the way  
4. Department of Health (2012) Steering group report on a 
national substance misuse strategy. Department of Health, 
Dublin. http://www.drugsandalcohol.ie/16908/ 
5. North West Alcohol Forum Ltd (NWAF) is an NGO 
established to work in partnership with all sectors to reduce 
hazardous drinking and its consequences to the individual, 
the family and the community.
6. Health Service Executive (2014) Primary care divisional 
operational plan 2015. Dublin: HSE. http://www.
drugsandalcohol.ie/23193/ 
7. Department of Community, Rural and Gaeltacht Affairs 
(2009) National Drugs Strategy (interim) 2009-2016. 
Dublin: Department of Community, Rural and Gaeltacht 
Affairs. http://www.drugsandalcohol.ie/12388/
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that the DCYA offers incentives for high programme 
performance and issues sanctions for poor programme 
performance’ (p. 126). 
(Martin Keane) 
1. Department of Children and Youth Affairs (2014) Value 
for money and policy review of the youth programmes that 
target disadvantaged young people. Dublin: Government 
Publications. http://www.drugsandalcohol.ie/23242/ 
2.  The DEIS (Delivering Equality of Opportunity in Schools) 
programme is the Department of Education and Skills’ 
policy instrument to address educational disadvantage. 
Currently 849 schools are included in the DEIS programme.
Youth programmes (continued)
It’s ‘Talk Time – what women want’
For the third year in a row, women from all over Ireland have 
come together to discuss issues relating to their experiences 
as ‘women in addiction and in addiction services’. The 
themes in the previous two years were My Story in Recovery, 
and Ten Tips for Professionals Working with Women in 
Addiction (see box). This year women were asked to work on 
‘a message for the Minister’.
Organised by SAOL, a community-based recovery project 
for women in Dublin’s north inner city, and UISCE (Union 
for Improved Services Communication and Education), a 
drug users forum based in Dublin’s north inner city, the 
forum was held in the Sheriff Street Football Club on 4 
March 2015.1 Some 100 women, including women from 
Cork and Belfast, attended the forum and local TDs Maureen 
O’Sullivan and Mary-Lou MacDonald spoke to the group. 
O’Sullivan talked about the importance of prevention in 
tackling the drug problem and the need also to tackle the 
housing and homelessness problems. MacDonald stressed 
that communities as a whole have a responsibility to tackle 
the drug problem and invited service users to let their 
communities, including their TDS, know what their needs 
and issues are. 
In breakout groups the women addressed three  
open-ended questions:
1. What is the number one thing that you think should be 
provided in services, which are presently not available?
2. If you could change one thing to positively change the 
drug scene in Ireland, what would it be?
3. What responses do women need from the government 
to help the unhealthy relationship with alcohol?
The breakout groups reported back on the outcomes of their 
discussions. These report-backs will be written up in a draft 
document outlining how to improve addiction services for 
women. Once peers from SAOL have checked the contents 
of the draft document with as many of the projects that 
attended Talktime 3 as possible, the report will be finalised 
and sent to the Minister for the National Drugs Strategy, to 
the north inner-city local drugs and alcohol task force and to 
Citywide.  It will also be published in Brass Munkie and on 
SAOL’s website.
(Brigid Pike)
1. For more information on SAOL and UISCE visit www.
saolproject.ie and www.nicdtf.ie/PROJECTS/PROJECTS/
UISCE.html 
Top Ten Tips for Professionals Working with Women in Addiction*
1. Don't be rushing us, because real recovery takes time. Smaller, women-only groups, will help.
2. Don’t judge us; get rid of the negative attitude; no discrimination. Women in recovery have enough shame already, 
we don’t need more. 
3. We want real empathy with practical support – not small talk with no action from you. If we didn’t need some 
practical help, we wouldn’t be at your services.
4. We need more women key-workers for women service users; then let us choose.
5. Work with us in partnership. We don’t need you to make decisions for us.
6. Make appointment times more flexible as there are more barriers for women when accessing services.
7. We need more residential options for mothers and babies. There’s often no point sending us to places when we have 
to leave our children behind.
8. Childcare services and resources are essential. We need more.
9. We need more social events for women as it is often harder for us to socialise and make friends when recovery gets 
under way.
10. We need practical help (including funding) with housing, general health and back to education. 
*Source: ‘It’s talk time 2’, SAOL 2014
Participants in the forum organised by SAOL and UISCE in the 
Sheriff Street Football Club on 4 March 2015.
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EMCDDA Perspectives on Drugs
The Perspective on Drugs (PODs) series was initiated by the 
European Monitoring Centre on Drugs and Drug Addiction 
(EMCDDA) in 2013 as an accompaniment to its annual 
European Drug Report. The PODs provide online interactive 
analyses and a deeper perspective on a selection of important 
issues. Individual PODs are updated as new developments 
occur. The PODs introduced to date are summarised below and 
can be found at http://www.emcdda.europa.eu/topics-a-z 
Mass media campaigns for the prevention of drug use in 
young people
The use of mass media campaigns in drug prevention is 
both relatively common and not without controversy. Both 
policymakers and practitioners have hotly debated the 
effectiveness of such campaigns. This POD reviews available 
evidence on the topic.
Hepatitis C treatment for injecting drug users
Transmitted through the sharing of needles, syringes and 
other injecting equipment, hepatitis C is the most common 
infectious disease among injecting drug users in Europe today. 
This analysis looks at some of the positive advances in treating 
the disease, including a new generation of medicines.
Preventing overdose deaths in Europe
It is estimated that over 70,000 lives were lost to drug 
overdoses in Europe in the first decade of the 21st century. 
Reducing drug-related deaths, therefore, remains a major 
challenge for public health policy. This POD describes some 
of the factors that increase the risk of fatal and non-fatal 
overdoses and a number of interventions developed to prevent 
these events.
Treatment for cocaine dependence 
The EMCDDA has carried out a meta-analysis of six reviews 
examining the effectiveness of medications used in treating 
cocaine problems. The original reviews, undertaken by the 
Cochrane Drugs and Alcohol Group, involved 92 studies (85 
in the US) and over 7,000 participants. This POD shows how 
some medications can reduce specific symptoms, but no 
single pharmacological solution has been found for cocaine 
dependence per se.
Emergency health consequences of cocaine use in Europe
Several thousand cocaine-related emergencies are reported 
in Europe every year. This POD studies the type of cocaine-
related problems reported and the potential of using hospital 
emergency data for monitoring acute problems associated with 
this drug.
Trends in heroin use in Europe: what do treatment demand 
data tell us?
Understanding heroin use trends in Europe is crucial on 
account of the considerable public health impact of this drug. 
Treatment demand data are analysed in this POD to assess 
changes over time in the number of first-time entrants to 
treatment who report heroin as their main problem drug.
Characteristics of frequent and high-risk cannabis users
Cannabis is Europe’s most commonly used illicit drug, with 
around 20 million adults (15–64 years) having used it in the 
last year, and around 3 million on a daily, or almost daily, basis. 
This POD explores the characteristics of frequent and high-risk 
cannabis users and reflects on how examination of this group 
can help design tailored interventions for those most at risk.
Models for the legal supply of cannabis
The three UN Conventions provide the international legal 
framework on drug control, instructing countries to limit drug 
supply and use to medical and scientific purposes. Yet, debate 
continues on the decriminalisation, or even legalisation, of 
drugs, particularly cannabis. Models under development for 
the legal supply of cannabis are described in this POD, as well 
as some of the questions they raise.
New developments in Europe’s cannabis market 
Europe has long been one of the world’s largest consumer 
markets for cannabis, particularly resin imported mainly from 
Morocco. In this analysis, the EMCDDA reports how Europe’s 
consumer market for cannabis is increasingly dominated by 
herbal products, with domestic herbal production supplying 
national markets. It also describes how imported cannabis resin 
appears to be getting stronger. 
Synthetic cannabinoids in Europe
Synthetic cannabinoids represent the largest group of 
compounds currently monitored in Europe by the EU 
early-warning system on new psychoactive substances. 
Current knowledge on these substances, as well as trends in 
production, availability and use, are presented in this analysis.
Synthetic drug production in Europe
Synthetic drugs have been produced illicitly in Europe for 
over 40 years and, by global standards, Europe is a significant 
producer. Described in this POD are current trends in illicit 
synthetic drug production
Injection of synthetic cathinones 
Over 50 synthetic cathinone derivatives were detected via the 
EU early-warning system between 2005 and 2013. This POD 
explores worrying new localised and national outbreaks of 
injecting these substances and recommends close monitoring 
of the issue as a public health priority.
Health and social responses to methamphetamine use 
Methamphetamine is an established stimulant drug in many 
parts of the world (e.g. south-east Asia and the US), where 
it has long caused major public health problems. While 
methamphetamine use in Europe has historically been confined 
to the Czech Republic and Slovakia, new pockets and patterns 
of use are now emerging elsewhere in the EU, in diverse 
populations. In this analysis, the EMCDDA looks at challenges 
for the provision of health and social responses to this drug.
Internet-based drug treatment 
Over the past 10 years the Internet has become recognised as 
a credible vehicle for delivering drug and alcohol education, 
prevention and treatment programmes. This POD charts 
developments in Internet-based drug treatment and explores 
some of the benefits it can offer.
Wastewater analysis and drugs 
The findings of the largest European project to date in the 
emerging science of wastewater analysis are described in this 
POD. The project in question analysed wastewater in over 
40 European cities (21 countries) to explore the drug-taking 
habits of those who live in them. The results reveal marked 
geographical variations.
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High-risk drug use and treatment 
Cited from Drugnet Europe No 88,  
October–December 2014
‘Continuity and change: high-risk drug use and drug 
treatment in Europe’ was the focus of a series of events held 
at the EMCDDA in September 2014. Two parallel expert 
meetings, dedicated to the agency’s treatment demand key 
indicator (TDI) and to the problem drug use indicator (PDU), 
preceded a broader, common event open to specialists from 
outside the two expert groups. 
While the two key indicator expert meetings explored 
important technical issues related to the implementation 
of these tools, the conference-style meeting focused on 
data- and multi-indicator analyses and monitoring drug 
treatment (as an epidemiological data source and a response 
to the drugs problem). Issues debated included trends 
and developments in high-risk opioid use; ageing drug 
users; vulnerable populations; high-risk use of stimulants, 
benzodiazepines and cannabis; treatment outcomes; and 
evaluating best practice. 
Drug-related harms and responses 
Cited from Drugnet Europe No 88,  
October–December 2014
Latest evidence in the area of drug overdose and HCV and 
HIV infections among drug users was among the topics 
discussed during a week of events organised by the  
EMCDDA in October 2014. Two EMCDDA expert meetings, 
dedicated to the agency’s drug-related deaths and mortality 
key indicator (DRD) and the drug-related infectious diseases 
key indicator (DRID), were preceded by a satellite event 
focusing on the role of take-home naloxone in reducing 
opioid-related fatalities. 
Epidemiologists, clinicians, public health practitioners and 
representatives of civil society shared perspectives with the 
Reitox national focal points and international organisations. 
Among the issues highlighted was Europe’s hepatitis C virus 
(HCV) epidemic among people who inject drugs and the 
need for scaling up treatment. Treatment coverage for HCV is 
very low in Europe, compared to levels stipulated in current 
guidelines. But the potential to tackle the problem exists: 
effective HCV treatments have been available for some years 
and new treatments are being released. These, together with 
harm reduction measures, can contribute to the prevention 
of new infections and help control the epidemic. 
Also raised at the meetings were the resurgence in heroin-
related deaths in some European countries and new HIV 
infections related to the injection of stimulants.
Four new drugs to be placed under control 
Cited from Drugnet Europe No 88,  
October–December 2014
On 25 September 2014, EU Ministers adopted a European 
Commission proposal to control four new psychoactive 
substances (NPS) currently raising health concerns in Europe. 
With the decision, the substances 25I-NBOMe, AH-7921, 
MDPV and methoxetamine will be subject to control 
measures and criminal penalties throughout the EU. 
In April 2014, the extended EMCDDA Scientific Committee 
examined the four drugs and submitted its risk-assessment 
reports to the European Commission and the Council of the 
EU. On the basis of these, the Commission recommended 
to the Council on 16 June that the drugs be submitted 
to control measures, given that severe toxicity has been 
associated with their use. 
The final decision entered into force the day after its 
publication in the Official Journal of the European Union on 1 
October 2014. Member states now have one year to take the 
necessary measures to subject those substances to control 
measures and criminal penalties, as provided for under their 
legislation (complying with their obligations under the 1971 
United Nations Convention on Psychotropic Substances). 
Two other new psychoactive substances causing health 
concerns in Europe were risk-assessed by the EMCDDA 
extended Scientific Committee on 16 September 2014. The 
first of these is 4,4′-DMAR, a derivative of aminorex with 
psychostimulant properties, which has been available on the 
drug market since at least December 2012. The second is 
MT-45, a synthetic opioid investigated in the 1970s for its 
analgesic properties and detected for the first time on the 
European drug market in October 2013. Respectively, a total 
of 31 and 28 deaths have been associated with these drugs 
and, in all cases, the presence of the substance in biological 
samples was analytically confirmed. 
Pregnancy and opioid use: strategies  
for treatment 
Cited from Drugnet Europe No 88,  
October–December 2014
Illicit opioid consumption during pregnancy brings with 
it the risk of an increase in obstetric complications for the 
mother as well as a range of potential dangers for the child, 
both before and immediately after birth. The primary goal 
when treating opioid dependence in pregnant women 
is to stabilise the patient. Psychosocially-assisted opioid 
substitution treatment is the preferred first-line therapy 
for this group and several combinations of substitution 
medicines and psychosocial approaches are available. A 
newly-published EMCDDA Paper reviews methadone, 
buprenorphine and slow-release oral morphine, used in a 
range of combinations with cognitive behaviour approaches 
and contingency management, and identifies the strengths 
of each medicine and method. 
Available in English at: www.emcdda.europa.eu/
publications/emcdda-papers 
Drugnet Europe is the quarterly newsletter of the European 
Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA). It is available at www.emcdda.europa.eu.
If you would like a hard copy of the current or future 
issues, please contact:
Health Research Board, Grattan House, 67–72 Lower 
Mount Street, Dublin 2. 
Tel: 01 2345 148; Email: drugnet@hrb.ie
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Recent publications
The following abstracts are cited from recently published journal 
articles relating to the drugs situation in Ireland.
Hazardous alcohol consumption among university 
students in Ireland: a cross-sectional study 
Davoren MP, Shiely F, Byrne M and Perry IJ BMJ Open (2015) 
5 (e006045)
http://bmjopen.bmj.com/content/5/1/e006045.full.pd...
http://www.drugsandalcohol.ie/23350/
There is considerable evidence of a cultural shift towards 
heavier alcohol consumption among university students, 
especially women. This study aims to investigate the 
prevalence and correlates of hazardous alcohol consumption 
(HAC) among university students with particular reference to 
gender and to compare different modes of data collection in 
this population.
Description and outcome evaluation of Jigsaw: an 
emergent Irish mental health early intervention 
programme for young people
O’Keeffe L, O’Reilly A, O’Brien G, Buckley R and Illback RJ 
Irish Journal of Psychological Medicine (2015) early online 
http://www.drugsandalcohol.ie/23291/ 
Jigsaw is an early intervention mental health service 
developed by Headstrong which provides support to 
young people, aged 12–25 years, in 10 communities 
across Ireland. This study aimed to profile young people 
who availed of Jigsaw, in one calendar year, and to provide 
evidence that Jigsaw’s model facilitates the reduction of 
psychological distress.
How social context impacts on the development, 
identification and treatment of mental and substance use 
disorders among young people – a qualitative study of 
health care workers 
Leahy D, Schaffalitzky E, Armstrong C, Latham L, McNicholas 
F, Meagher D, Nathan Y, O’Connor R, O’Keane V, Ryan P, 
Smyth B, Swan D and Cullen W Irish Journal of Psychological 
Medicine (2015) early online 
http://www.drugsandalcohol.ie/23277/
Social context has a major influence on the detection and 
treatment of youth mental and substance use disorders in 
socio-economically disadvantaged urban areas, particularly 
where gang culture, community violence, normalisation of 
drug use and repetitive maladaptive family structures prevail. 
This paper aims to examine how social context influences 
the development, identification and treatment of youth 
mental and substance use disorders in socio-economically 
disadvantaged urban areas from the perspectives of health 
care workers.
‘Causes of causes’: ethnicity and social position as 
determinants of health inequality in Irish Traveller men
Hodgins M and Fox F Health Promotion International (2014) 
29(2): 223–234 
http://www.drugsandalcohol.ie/23272/
This study sought to engage Traveller men in a discussion 
about their lives, their health and key determinants of their 
health, with a view to engaging Traveller men in health 
promotion initiatives. Irish Travellers are an indigenous 
ethnic minority, constituting 0.8% of the population. 
As a marginalised group, they experience significantly 
poorer health status than their counterparts in the settled 
community. Traveller men have 3.7 times the mortality of 
the males in the general population. Travellers are identified 
as a hard-to-reach group and Traveller men particularly 
so. Traveller men have rarely participated in the research 
studies on health and health service utilization, and the 
results of this study, in which Traveller men participated in 
three focus groups, are therefore of particular interest. The 
Traveller men, in discussing health, related it to the absence 
of specific illnesses and conditions, expressing a negative and 
a physical concept of health. The results of the study provide 
evidence for the role of social constructions of masculinity 
in determining the health and help-seeking behaviour 
of Traveller men, but also the influence of wider social 
determinants such as ethnicity and social status. The futility 
of approaches to health promotion that comprise simplistic 
health information/education interventions is outlined in 
this context. The study presents a challenge to address both 
hegemonic versions of masculinity and discrimination based 
on ethnic status, and rather than challenge the behaviour of 
men or of health services that they come into contact with, 
to changing the conditions of Traveller men’s lives.
The association between parental and adolescent 
substance misuse: findings from the Irish CASE study 
Keeley HS, Mongwa T and Corcoran P Irish Journal of 
Psychological Medicine (2015) early online 
http://www.drugsandalcohol.ie/23244/
This article is described more fully in a report 'Adolescents 
and parental substance abuse' elsewhere in this issue of 
Drugnet Ireland. 
Hospital-treated deliberate self-harm in the western area 
of Northern Ireland
Corcoran P, Griffin E, O’Carroll A, Cassidy L and Bonner B 
Crisis (2015) early online 
http://www.drugsandalcohol.ie/23287/ 
This study aims to establish the incidence of hospital-
treated deliberate self-harm in the western area of Northern 
Ireland, and to explore the profile of such presentations. 
Deliberate self-harm presentations made to the three hospital 
emergency departments operating in the area during the 
period 2007–2012 were recorded. 
There were 8,175 deliberate self-harm presentations by 
4,733 individuals. Respectively, the total male and female 
age-standardised incidence rate was 342, 320, and 366 
per 100,000 population. City council residents had a far 
higher self-harm rate. The peak rate for women was among 
15–19-year-olds (837 per 100,000), and for men among 
20–24-year-olds (809 per 100,000). Risk of repetition was 
higher in 35–44-year-old patients if self-cutting was involved, 
but was most strongly associated with the number of 
previous self-harm presentations. 
The incidence of hospital-treated self-harm in Northern 
Ireland is far higher than in the Republic of Ireland and more 
comparable to that in England.
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Parental rules, parent and peer attachment, and 
adolescent drinking behaviors
McKay MT Substance Use & Misuse (2015) 50(2): 184–188
http://www.drugsandalcohol.ie/22795/ 
Family factors have been widely implicated in the 
development of adolescent drinking behaviours. These 
include parental attachment and parental rules concerning 
drinking behaviours. Moreover, throughout adolescence 
attachment to parents gives way to attachment to peers, 
and parental rules about alcohol use become less strict. The 
present study examined the relationship between parental 
and peer attachment, parental rules on drinking and alcohol 
use in a large sample (n=1,724) of adolescents in the United 
Kingdom. Controlling for school grade (proxy for age), 
sex and the non-independence of respondents (clustering 
at school level), results showed that scores on a parental 
rules on drinking questionnaire were a significant statistical 
predictor when comparing moderate drinkers and abstainers, 
as well as moderate drinkers and problematic drinkers. Scores 
on both attachment scales were also significant, but only in 
the comparison between moderate and problematic drinkers, 
with lower attachment to parents and higher attachment to 
peers associated with problematic drinking.
Modeling the impact of place on individual methadone 
treatment outcomes in a national longitudinal cohort 
study
Murphy E and Comiskey CM Substance Use & Misuse (2015) 
50(1): 99–105 
http://www.drugsandalcohol.ie/22782/
Little has been published on the effect of geography on 
methadone treatment outcomes. This study aims to measure 
the effect of place on longitudinal outcomes. From 2003 
to 2006, 215 clients were recruited to a cohort study of 
methadone treatment. Participants had their address and 
clinic geocoded. Treatment outcomes were measured at 
intake, at one and three years post-treatment, using the 
Maudsley Addiction Profile instrument. Spider diagrams and 
buffer rings were used to visually map clinics and clients. 
Regression models were used to measure the effect of place. 
Clients’ accommodation and social and criminal problems 
in the region had a medium to large effect on heroin use. 
Analysis of buffer rings revealed that clients located within 
a 10-km radius of a major clinic demonstrated poorer 
outcomes in terms of heroin use. Findings illustrated the 
relevance of geography on drug treatment outcomes and 
the planning of services.
Pregabalin abuse for enhancing sexual performance: case 
discussion and literature review
Osman M and Casey P Irish Journal of Psychological Medicine 
(2014) 3(4): 281–286 
http://www.drugsandalcohol.ie/22563/
Pregabalin is a γ-aminobutyric acid analogue that is primarily 
prescribed in psychiatry for management of generalised 
anxiety disorder. The belief in its low potential for abuse has 
placed it in a superior position to other anxiolytic agents. 
However, more recent concerns have been raised about 
the addictive potential of pregabalin. This problem has 
not received much attention nor has the mechanism of its 
development. There is also a lack of understanding of the 
difference in the experience of abusing pregabalin in contrast 
to abusing other illicit drugs. 
We report the case of a 55-year-old patient with a 
background history of multiple psychoactive substances 
misuse who elaborated on his own personal experience of 
pregabalin abuse. He consumed a month’s supply of this 
medication over two days and realised an enhancement 
in sexual desire and excitement. This effect should be 
considered when prescribing pregabalin.
Cigarette smoking impairs human pulmonary immunity 
to mycobacterium tuberculosis
O’Leary SM, Coleman MM, Chew WM, Morrow C, 
McLaughlin AM, Gleeson LE, O’Sullivan MP and Keane J 
American Journal of Respiratory and Critical Care Medicine 
(2014) 190(12): 1430–1436 
http://www.drugsandalcohol.ie/22976/
Cigarette smoking is linked to important aspects of 
tuberculosis, such as susceptibility to infection, disease 
reactivation, mortality, transmission and persistent 
infectiousness. The mechanistic basis for this remains poorly 
understood. This study aims to compare the functional 
impairment, seen in human alveolar macrophages (AM) from 
non-smokers, smokers and ex-smokers, after infection with 
Mycobacterium tuberculosis (Mtb). 
Sexually transmitted infection incidence among 
adolescents in Ireland 
Davoren MP, Kevin H, Horgan M and Shiely F The Journal of 
Family Planning and Reproductive Health Care (2014) 40 (4): 
276–282 
URL: http://www.ncbi.nlm.nih.gov/pmc/articles/
PMC417401...
http://www.drugsandalcohol.ie/23124/
The burden of sexually transmitted infections (STIs) rests 
with young people, yet in Ireland there has been very little 
research into this population. The purpose of this study was 
to determine the incidence rate and establish risk factors that 
predict STI occurrence among adolescents in Ireland.
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21 495 seizures amounting 
to almost 1.6 tonnes in 2013
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to more than 1.1 tonnes in 2013
101 NPS reported
for the rst time in 2014
>450 NPS currently monitored
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Sold as 'legal' replacements for stimulants
Synthetic cannabinoids
Sold as 'legal' replacements for cannabis EU Early Warning System
Since 1997, the EMCDDA has played a central role in 
Europe's response to new psychoactive substances.  
Its main responsibilities in this eld are to operate the 
EU Early Warning System, with its partner Europol, and 
to undertake risk assessments of new substances 
when necessary. e EU Early Warning System works 
by collecting information on the appearance of new 
substances from the 28 EU Member States, Turkey 
and Norway, and then monitoring them for signals of 
harm, allowing the EU to respond rapidly to emerging 
threats. 
Synthetic cannabinoids (left panel) and synthetic 
cathinones (right) make up the largest groups of new 
psychoactive substances monitored by the EMCDDA 
and, respectively, reect the demand for cannabis and 
stimulants in Europe. However, the EMCDDA also 
monitors many new substances that come from a 
range of other groups, including phenethylamines, 
opioids, tryptamines, benzodiazepines, 
arylalkylamines and piperazines. All these substances 
require monitoring in order to identify signals of serious 
harms as early as possible. Opioids, for example, are of 
special concern for public health because they pose a 
very high risk of overdose and death. During 2014, 
serious harms that required urgent attention led to    
16 public health alerts being issued by the EMCDDA, 
while 6 new substances — 25I-NBOMe, AH-7921, 
methoxetamine, MDPV, 4,4′-DMAR and MT-45 — 
required risk assessment by the EMCDDA's Scientic 
Committee.
Read the full report at
emcdda.europa.eu/publications/2015/new-psychoactive-substances
Number of seizures Quantity seized, powder only (kg)
2005 2006 2007 2008 2009 2010 2011 2012 2013
12 000
10 000
8 000
6 000
4 000
2 000
1 200
1 000
800
600
400
200
Number of synthetic cathinone seizures and quantity seized,
 2005–13
Number of synthetic cannabinoid seizures and quantity seized, 
2008–13
Number of seizures Quantity seized (kg)
400
800
1 200
1 600
2 000
2008 2009 2010 2011 2012 2013
5 000
10 000
15 000
20 000
25 000
60-fold increase
in seizures 2008–13
Number of synthetic cathinone seizures and proportion of 
seizures by substance, 2013
>500
100–499
50–99
10–49
<10
alphaPVP
10 %
MDPV
9 %
Other
pyrrolidinyl cathinones
3 %
Other cathinone derivatives
23 %
Pentedrone
14 %
Methylone
7 %
Mephedrone
20 %
3,4 DMMC
2 %
4 MEC
12 %
200-fold increase
in seizures 2008–13
Number of NPS seizures and quantity seized, 2005–13
1 600
800
2 400
3 200
4 000
10 000
20 000
30 000
40 000
50 000
2005 200820072006 2009 2010 2011 2012 2013
in seizures 2008–13
7-fold increase
Number of seizures Quantity seized (kg)
 
New psychoactive substances in Europe
e market 
Legal highs
Marketed in bright and attractive 
packaging. Sold openly in head/smart 
shops and online. Aimed at recreational 
users.
Research chemicals
Sold under the guise of being used for 
scientic research. Aimed at 
'psychonauts' who explore the e¥ects of 
psychoactive substances. Sold openly 
online.
Food supplements
Sold under the guise of being food or 
dietary supplements. Aimed at people 
wanting to enhance their body and mind. 
Sold openly in tness shops and online.
Designer drugs
Passed o¥ as drugs such as MDMA and 
heroin. Produced in clandestine labs by 
organised crime. Sold on illicit drug 
market by drug dealers. 
Medicines
Medicines that are diverted from patients 
or illegally imported into Europe. Sold on 
illicit drug market by drug dealers.    
New psychoactive substances (NPS) — at a glance
From synthesis to consumer
Chemical companies based in China and 
India synthesise NPS in bulk quantity 
Shipped by air or sea to Europe  Processed and packaged into legal highs, research 
chemicals and food supplements
Sold openly in head/smart 
shops and online 
8 % of young adults have 
used NPS in their life 
(Eurobarometer)
An update from the EU Early Warning System (March 2015)  info@emcdda.europa.eu | emcdda.europa.eu
